G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845","Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.citation.ru":["Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.citation.en":["Liu Q., Lyu H., Xu B., Lee J.H. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–86. DOI: 10.1007/s00266-020-02083-5","Sia K.J., Tang I.P., Tan T.Y. Multiple symmetrical lipomatosis: case report and literature review. J Laryngol Otol. 2012;126(7):756–8. DOI: 10.1017/S0022215112000709","Kratz C., Lenard H.G., Ruzicka T., Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–7. DOI: 10.1053/ejpn.2000.0264","Nounla J., Rolle U., Gräfe G., Kräling K. Benign symmetric lipomatosis with myelomeningocele in an adolescent: An uncommon association-case report. J Pediatr Surg. 2001;36(7):E13. DOI: 10.1053/jpsu.2001.24776","Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30.","Lanois P.E., Bensaude R. De ladeno-lipomatosesymetrique. Bull Mem Soc Med Hosp. 1898;1:298.","El Ouahabi H., Doubi S., Lahlou K., Boujraf S., Ajdi F. Launois-bensaude syndrome: A benign symmetric lipomatosis without alcohol association. Ann Afr Med. 2017;16(1):33–4. DOI: 10.4103/1596-3519.202082","Chen C.Y., Fang Q.Q., Wang X.F., Zhang M.X., Zhao W.Y., Shi B.H., et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;3975974. DOI: 10.1155/2018/3975974","Coker J.E., Bryan J.A. Endocrine and metabolic disorders: Causes and pathogenesis of obesity. J. Fam. Pract. 2008;4:21–6.","González-García R., Rodríguez-Campo F.J., Sastre-Pérez J., Muñoz-Guerra M.F. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108– 12; discussion 113. DOI: 10.1007/s00266-004-3123-5","Holme E., Larsson N.G., Oldfors A., Tulinius M., Sahlin P., Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNA(Lys) A-->G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993r;52(3):551–6. PMID: 8447321","Мазунин И.О., Володько Н.В., Стариковская Е.Б., Сукерник Р.И. Митохондриальный геном и митохондриальные заболевания человека. Молекулярная биология. 2010;44(5):755–72.","Celentano V., Esposito E., Perrotta S., Giglio M.C., Tarquini R., Luglio G., et al. Madelung disease: report of a case and review of the literature. Acta Chir Belg. 2014;114(6):417–20. PMID: 26021689","Lemaitre M., Chevalier B., Jannin A., Bourry J., Espiard S., Vantyghem M.C. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. DOI: 10.1016/j.lpm.2021.104077","Вецмадян Е.А., Труфанов Г.Е., Рязанов В.В., Мостовая О.Т., Новиков К.В., Карайванов Н.С. Ультразвуковая диагностика липом мягких тканей с использованием методик цветного допплеровского картирования и эластографии. Вестник Российской Военно-медицинской академии. 2012;2(38):43–50.","Богов А.А., Андреев П.С., Филиппов В.Л., Топыркин В.Г. Оперативное лечение болезни Маделунга. Практическая медицина. 2018;16(7-1):90–3.","Уракова Е.В., Нестеров О.В., Ильина Р.Ю., Лексин Р.В. Хирургическая тактика при рецидивирующем липоматозе (болезни Маделунга). Клинический случай. Практическая медицина. 2022;20(6):131–3.","Егай А.А., Тентимишев А.Э., Норматов Р.М., Тян А.С. Хирургическое лечение множественного симметричного липоматоза (болезнь Маделунга), осложненного сдавлением яремных вен с обеих сторон. Преимущества липэктомии перед липосакцией. Научное обозрение. Медицинские науки. 2022;1:5– 10. DOI: 10.17513/srms.1225","Тимербулатов М.В., Шорнина А.С., Лихтер Р.А., Каипов А.Э. Оценка липосакции в структуре абдоминопластики и сочетанной герниоабдоминопластики. Креативная хирургия и онкология. 2023;13(4):278–83. DOI: 10.24060/2076-3093-2023-13-4-278-283","Dang Y., Du X., Ou X., Zheng Q., Xie F. Advances in diagnosis and treatment of Madelung’s deformity. Am J Transl Res. 2023;15(7):4416–24.","Leti Acciaro A, Garagnani L, Lando M, Lana D, Sartini S, Adani R. Modified dome osteotomy and anterior locking plate fixation for distal radius variant of Madelung deformity: a retrospective study. J Plast Surg Hand Surg. 2022;56(2):121–6. DOI: 10.1080/2000656X.2021.1934845"],"dc.identifier.uri":["http://hdl.handle.net/123456789/8932"],"dc.date.accessioned_dt":"2025-07-09T13:59:02Z","dc.date.accessioned":["2025-07-09T13:59:02Z"],"dc.date.available":["2025-07-09T13:59:02Z"],"publication_grp":["123456789/8932"],"bi_4_dis_filter":["madelung’s disease\n|||\nMadelung’s disease","lipectomy\n|||\nlipectomy","диффузный симметричный липоматоз\n|||\nдиффузный симметричный липоматоз","шеи новообразования\n|||\nшеи новообразования","липэктомия\n|||\nлипэктомия","diffuse symmetric lipomatosis\n|||\ndiffuse symmetric lipomatosis","adipose tissue proliferation\n|||\nadipose tissue proliferation","жировой ткани разрастание\n|||\nжировой ткани разрастание","болезнь маделунга\n|||\nболезнь Маделунга","neck neoplasms\n|||\nneck neoplasms"],"bi_4_dis_partial":["липэктомия","Madelung’s disease","diffuse symmetric lipomatosis","neck neoplasms","болезнь Маделунга","adipose tissue proliferation","шеи новообразования","lipectomy","диффузный симметричный липоматоз","жировой ткани разрастание"],"bi_4_dis_value_filter":["липэктомия","Madelung’s disease","diffuse symmetric lipomatosis","neck neoplasms","болезнь Маделунга","adipose tissue proliferation","шеи новообразования","lipectomy","диффузный симметричный липоматоз","жировой ткани разрастание"],"bi_sort_1_sort":"systemic benign lipomatosis (madelung’s disease): experience of surgical treatment. clinical case","bi_sort_3_sort":"2025-07-09T13:59:02Z","read":["g0"],"_version_":1837178072511545344},{"SolrIndexer.lastIndexed":"2022-10-06T05:10:25.685Z","search.uniqueid":"2-5704","search.resourcetype":2,"search.resourceid":5704,"handle":"123456789/6609","location":["m229","l684"],"location.comm":["229"],"location.coll":["684"],"withdrawn":"false","discoverable":"true","dc.abstract":["New (2,2-dimethyl-1,3-dioxolan-4-yl)methyl esters, (5-ethyl-1,3-dioxan-5-yl)methyl, (1,3-dioxolan-4-yl)methyl and 1,3-dioxane-5-yl esters of abietic and maleopimaric acids) were synthesized and studied their cytotoxic activity. It was shown that the use of sodium salts of the corresponding dioxacyclane alcohols allows the synthesis of esters with high selectivity and yields of 75-80%, preventing the formation of by-products, and facilitates the reaction. The starting compounds (acid chlorides and 1,3-dioxacycloalkanes) were synthesized according to standard basic procedures. A mixture of the esters was obtained with the predominance of the 5-membered cyclic derivative (1,3-dioxolane) over the 6-membered structure (1, 3-dioxane) from glycerol formals (1,3-dioxolan-4-ylmethanol and 1,3-dioxan-5-ol). This is due to the greater activity in the esterification reaction of the alcoholate of the primary alcohol than that of the secondary one. The total yield of the reaction products does not exceed 70%. The cytotoxic activity of the synthesized compounds was studied on tumor cell cultures A549 - human lung carcinoma; MCF-7, breast adenocarcinoma; HEK293 - conditionally normal embryonic human kidney cells and SH-SY5Y - human neuroblastoma cell line. Evaluation of the effect of cycloacetal esters on cell viability was carried out using the vital dye PrestoBlue (R) according to the manufacturer's protocol (Invitrogen, USA) in vitro at a substance concentration of 1, 10, and 100 mu M). The test results showed that the obtained new (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester of maleopimaric acid does not affect the metabolic activity of HEK293 cells and does not exhibit cytotoxic properties, while 5-ethyl-1,3- dioxan-5-yl) methyl ester of maleopimaric acid turned out to be a low-toxic compound in relation to all cell lines at the concentration used. The data obtained substantiate the prospects for studying and creating biologically active (antimicrobial, anticoagulant, antiaggregatory and antiviral) drugs with a wide spectrum of action on the basis of the obtained esters."],"dc.abstract.en":["New (2,2-dimethyl-1,3-dioxolan-4-yl)methyl esters, (5-ethyl-1,3-dioxan-5-yl)methyl, (1,3-dioxolan-4-yl)methyl and 1,3-dioxane-5-yl esters of abietic and maleopimaric acids) were synthesized and studied their cytotoxic activity. It was shown that the use of sodium salts of the corresponding dioxacyclane alcohols allows the synthesis of esters with high selectivity and yields of 75-80%, preventing the formation of by-products, and facilitates the reaction. The starting compounds (acid chlorides and 1,3-dioxacycloalkanes) were synthesized according to standard basic procedures. A mixture of the esters was obtained with the predominance of the 5-membered cyclic derivative (1,3-dioxolane) over the 6-membered structure (1, 3-dioxane) from glycerol formals (1,3-dioxolan-4-ylmethanol and 1,3-dioxan-5-ol). This is due to the greater activity in the esterification reaction of the alcoholate of the primary alcohol than that of the secondary one. The total yield of the reaction products does not exceed 70%. The cytotoxic activity of the synthesized compounds was studied on tumor cell cultures A549 - human lung carcinoma; MCF-7, breast adenocarcinoma; HEK293 - conditionally normal embryonic human kidney cells and SH-SY5Y - human neuroblastoma cell line. Evaluation of the effect of cycloacetal esters on cell viability was carried out using the vital dye PrestoBlue (R) according to the manufacturer's protocol (Invitrogen, USA) in vitro at a substance concentration of 1, 10, and 100 mu M). The test results showed that the obtained new (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester of maleopimaric acid does not affect the metabolic activity of HEK293 cells and does not exhibit cytotoxic properties, while 5-ethyl-1,3- dioxan-5-yl) methyl ester of maleopimaric acid turned out to be a low-toxic compound in relation to all cell lines at the concentration used. The data obtained substantiate the prospects for studying and creating biologically active (antimicrobial, anticoagulant, antiaggregatory and antiviral) drugs with a wide spectrum of action on the basis of the obtained esters."],"author":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM","Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"author_keyword":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM","Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"author_ac":["khusnutdinova, ns\n|||\nKhusnutdinova, NS","sakhabutdinova, gn\n|||\nSakhabutdinova, GN","raskil'dina, gz\n|||\nRaskil'dina, GZ","meshcheryakova, sa\n|||\nMeshcheryakova, SA","zlotsky, ss\n|||\nZlotsky, SS","sultanova, rm\n|||\nSultanova, RM","хуснутдинова, н.с.\n|||\nХуснутдинова, Н.С.","сахабутдинова, г.н.\n|||\nСахабутдинова, Г.Н.","раскильдина, г.з.\n|||\nРаскильдина, Г.З.","мещерякова, с.а.\n|||\nМещерякова, С.А.","злотский, с.с.\n|||\nЗлотский, С.С.","султанова, р.м.\n|||\nСултанова, Р.М."],"author_filter":["khusnutdinova, ns\n|||\nKhusnutdinova, NS","sakhabutdinova, gn\n|||\nSakhabutdinova, GN","raskil'dina, gz\n|||\nRaskil'dina, GZ","meshcheryakova, sa\n|||\nMeshcheryakova, SA","zlotsky, ss\n|||\nZlotsky, SS","sultanova, rm\n|||\nSultanova, RM","хуснутдинова, н.с.\n|||\nХуснутдинова, Н.С.","сахабутдинова, г.н.\n|||\nСахабутдинова, Г.Н.","раскильдина, г.з.\n|||\nРаскильдина, Г.З.","мещерякова, с.а.\n|||\nМещерякова, С.А.","злотский, с.с.\n|||\nЗлотский, С.С.","султанова, р.м.\n|||\nСултанова, Р.М."],"dc.contributor.author_hl":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM","Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"dc.contributor.author_mlt":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM","Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"dc.contributor.author":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM","Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"dc.contributor.author_stored":["Khusnutdinova, NS\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Sakhabutdinova, GN\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Raskil'dina, GZ\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Meshcheryakova, SA\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Zlotsky, SS\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Sultanova, RM\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Хуснутдинова, Н.С.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Сахабутдинова, Г.Н.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Раскильдина, Г.З.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Мещерякова, С.А.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Злотский, С.С.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Султанова, Р.М.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU"],"dc.contributor.author.en":["Khusnutdinova, NS","Sakhabutdinova, GN","Raskil'dina, GZ","Meshcheryakova, SA","Zlotsky, SS","Sultanova, RM"],"dc.contributor.author.ru_RU":["Хуснутдинова, Н.С.","Сахабутдинова, Г.Н.","Раскильдина, Г.З.","Мещерякова, С.А.","Злотский, С.С.","Султанова, Р.М."],"dc.date.accessioned_dt":"2022-04-21T06:50:56Z","dc.date.accessioned":["2022-04-21T06:50:56Z"],"dc.date.available":["2022-04-21T06:50:56Z"],"dateIssued":["2022-01-01"],"dateIssued_keyword":["2022-01-01","2022"],"dateIssued_ac":["2022-01-01\n|||\n2022-01-01","2022"],"dateIssued.year":[2022],"dateIssued.year_sort":"2022","dc.date.issued_dt":"2022-01-01T00:00:00Z","dc.date.issued":["2022-01-01"],"dc.date.issued_stored":["2022-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.description.abstract_hl":["Получены новые сложные эфиры (2,2-диметил-1,3-диоксолан-4-ил)метиловые, (5-этил-1,3-диоксан-5-ил)метиловые, (1,3-диоксолан-4-ил)метиловые и 1,3-диоксан-5-иловые эфиры абиетиновой и малеопимаровой кислот) и изучена их цитотоксическая активность. Показано, что применение натриевых солей соответствующих диоксациклановых спиртов позволяет синтезировать сложные эфиры с высокой селективностью и выходами 75-80%, препятствуя образованию побочных продуктов, и облегчает протекание реакции. Исходные соединения (хлорангидриды и 1,3-диоксациклоалканы) получены согласно стандартным базо-вым методикам. Из формалей глицерина (1,3-диоксолан-4-илметанола и 1,3-диоксан-5-ола) синтезирована смесь соответствующих эфиров с преобладанием 5-звенного циклического про-изводного (1,3-диоксолана) над 6-звенной структурой (1,3-диоксаном). Это связано с большей активностью в реакции этерификации алкоголята первичного спирта, чем вторичного. Об-щий выход продуктов реакции не превышает 70%. Цитотоксическую активность полученных соединений изучали на опухолевых культурах клеток A549 –карцинома легкого человека; MCF-7 –аденокарцинома молочной железы; HEK293 –условно-нормальные эмбриональные клетки почки человека и SH-SY5Y –линия клеток нейробластомы человека. Оценка влияния цикло-ацетальных эфиров на жизнеспособность клеток проведена с помощью витального краси-теля PrestoBlue® согласно протоколу изготовителя (Invitrogen, США) in vitro при концентра-ции вещества 1, 10 и 100 мкМ). Результаты тестирования показали, что полученный новый (2,2-диметил-1,3-диоксолан-4-ил)метиловый эфир малеопимаровой кислоты не влияет на ме-таболическую активность клеток HEK293 и не проявляет цитотоксические свойства, а 5-этил-1,3-диоксан-5-ил)метиловый эфир малеопимаровой кислоты оказался малотоксичным соединением по отношению ко всем клеточным линиям в используемой концентрации. Полу-ченные данные обосновывают перспективность изучения и создания на основе полученных сложных эфиров биологически активных (противомикробных, антикоагуляционных, антиа-грегационных и противовирусных) препаратов с широким спектром действия."],"dc.description.abstract":["Получены новые сложные эфиры (2,2-диметил-1,3-диоксолан-4-ил)метиловые, (5-этил-1,3-диоксан-5-ил)метиловые, (1,3-диоксолан-4-ил)метиловые и 1,3-диоксан-5-иловые эфиры абиетиновой и малеопимаровой кислот) и изучена их цитотоксическая активность. Показано, что применение натриевых солей соответствующих диоксациклановых спиртов позволяет синтезировать сложные эфиры с высокой селективностью и выходами 75-80%, препятствуя образованию побочных продуктов, и облегчает протекание реакции. Исходные соединения (хлорангидриды и 1,3-диоксациклоалканы) получены согласно стандартным базо-вым методикам. Из формалей глицерина (1,3-диоксолан-4-илметанола и 1,3-диоксан-5-ола) синтезирована смесь соответствующих эфиров с преобладанием 5-звенного циклического про-изводного (1,3-диоксолана) над 6-звенной структурой (1,3-диоксаном). Это связано с большей активностью в реакции этерификации алкоголята первичного спирта, чем вторичного. Об-щий выход продуктов реакции не превышает 70%. Цитотоксическую активность полученных соединений изучали на опухолевых культурах клеток A549 –карцинома легкого человека; MCF-7 –аденокарцинома молочной железы; HEK293 –условно-нормальные эмбриональные клетки почки человека и SH-SY5Y –линия клеток нейробластомы человека. Оценка влияния цикло-ацетальных эфиров на жизнеспособность клеток проведена с помощью витального краси-теля PrestoBlue® согласно протоколу изготовителя (Invitrogen, США) in vitro при концентра-ции вещества 1, 10 и 100 мкМ). Результаты тестирования показали, что полученный новый (2,2-диметил-1,3-диоксолан-4-ил)метиловый эфир малеопимаровой кислоты не влияет на ме-таболическую активность клеток HEK293 и не проявляет цитотоксические свойства, а 5-этил-1,3-диоксан-5-ил)метиловый эфир малеопимаровой кислоты оказался малотоксичным соединением по отношению ко всем клеточным линиям в используемой концентрации. Полу-ченные данные обосновывают перспективность изучения и создания на основе полученных сложных эфиров биологически активных (противомикробных, антикоагуляционных, антиа-грегационных и противовирусных) препаратов с широким спектром действия."],"dc.description.abstract.ru_RU":["Получены новые сложные эфиры (2,2-диметил-1,3-диоксолан-4-ил)метиловые, (5-этил-1,3-диоксан-5-ил)метиловые, (1,3-диоксолан-4-ил)метиловые и 1,3-диоксан-5-иловые эфиры абиетиновой и малеопимаровой кислот) и изучена их цитотоксическая активность. Показано, что применение натриевых солей соответствующих диоксациклановых спиртов позволяет синтезировать сложные эфиры с высокой селективностью и выходами 75-80%, препятствуя образованию побочных продуктов, и облегчает протекание реакции. Исходные соединения (хлорангидриды и 1,3-диоксациклоалканы) получены согласно стандартным базо-вым методикам. Из формалей глицерина (1,3-диоксолан-4-илметанола и 1,3-диоксан-5-ола) синтезирована смесь соответствующих эфиров с преобладанием 5-звенного циклического про-изводного (1,3-диоксолана) над 6-звенной структурой (1,3-диоксаном). Это связано с большей активностью в реакции этерификации алкоголята первичного спирта, чем вторичного. Об-щий выход продуктов реакции не превышает 70%. Цитотоксическую активность полученных соединений изучали на опухолевых культурах клеток A549 –карцинома легкого человека; MCF-7 –аденокарцинома молочной железы; HEK293 –условно-нормальные эмбриональные клетки почки человека и SH-SY5Y –линия клеток нейробластомы человека. Оценка влияния цикло-ацетальных эфиров на жизнеспособность клеток проведена с помощью витального краси-теля PrestoBlue® согласно протоколу изготовителя (Invitrogen, США) in vitro при концентра-ции вещества 1, 10 и 100 мкМ). Результаты тестирования показали, что полученный новый (2,2-диметил-1,3-диоксолан-4-ил)метиловый эфир малеопимаровой кислоты не влияет на ме-таболическую активность клеток HEK293 и не проявляет цитотоксические свойства, а 5-этил-1,3-диоксан-5-ил)метиловый эфир малеопимаровой кислоты оказался малотоксичным соединением по отношению ко всем клеточным линиям в используемой концентрации. Полу-ченные данные обосновывают перспективность изучения и создания на основе полученных сложных эфиров биологически активных (противомикробных, антикоагуляционных, антиа-грегационных и противовирусных) препаратов с широким спектром действия."],"dc.doi":["10.6060/ivkkt.20226504.6516"],"dc.identifier.issn":["0579-2991"],"dc.identifier.other":["УДК:547.914.5"],"dc.identifier.other.ru_RU":["УДК:547.914.5"],"dc.identifier.uri":["http://hdl.handle.net/123456789/6609"],"dc.publisher":["IVANOVSKOGO KHIMIKO-TEKHNOLOGI TSHESKOGO INSTPR-KT F ENGELSA 7, 153460 IVANOVO, RUSSIA"],"dc.publisher.en":["IVANOVSKOGO KHIMIKO-TEKHNOLOGI TSHESKOGO INSTPR-KT F ENGELSA 7, 153460 IVANOVO, RUSSIA"],"dc.relation.ispartofseries":["IZVESTIYA VYSSHIKH UCHEBNYKH ZAVEDENII KHIMIYA I KHIMICHESKAYA TEKHNOLOGIYA;т. 65 № 4"],"dc.relation.ispartofseries.en":["IZVESTIYA VYSSHIKH UCHEBNYKH ZAVEDENII KHIMIYA I KHIMICHESKAYA TEKHNOLOGIYA;т. 65 № 4"],"subject":["diterpene acids","1,3-dioxacycloalkanes","esters","chemical modification","cytotoxicity","Web of Science","дитерпеновые кислоты","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","цитотоксичность","ВАК"],"subject_keyword":["diterpene acids","diterpene acids","1,3-dioxacycloalkanes","1,3-dioxacycloalkanes","esters","esters","chemical modification","chemical modification","cytotoxicity","cytotoxicity","Web of Science","Web of Science","дитерпеновые кислоты","дитерпеновые кислоты","1,3-диоксациклоалканы","1,3-диоксациклоалканы","сложные эфиры","сложные эфиры","химическая модификация","химическая модификация","цитотоксичность","цитотоксичность","ВАК","ВАК"],"subject_ac":["diterpene acids\n|||\nditerpene acids","1,3-dioxacycloalkanes\n|||\n1,3-dioxacycloalkanes","esters\n|||\nesters","chemical modification\n|||\nchemical modification","cytotoxicity\n|||\ncytotoxicity","web of science\n|||\nWeb of Science","дитерпеновые кислоты\n|||\nдитерпеновые кислоты","1,3-диоксациклоалканы\n|||\n1,3-диоксациклоалканы","сложные эфиры\n|||\nсложные эфиры","химическая модификация\n|||\nхимическая модификация","цитотоксичность\n|||\nцитотоксичность","вак\n|||\nВАК"],"subject_tax_0_filter":["diterpene acids\n|||\nditerpene acids","1,3-dioxacycloalkanes\n|||\n1,3-dioxacycloalkanes","esters\n|||\nesters","chemical modification\n|||\nchemical modification","cytotoxicity\n|||\ncytotoxicity","web of science\n|||\nWeb of Science","дитерпеновые кислоты\n|||\nдитерпеновые кислоты","1,3-диоксациклоалканы\n|||\n1,3-диоксациклоалканы","сложные эфиры\n|||\nсложные эфиры","химическая модификация\n|||\nхимическая модификация","цитотоксичность\n|||\nцитотоксичность","вак\n|||\nВАК"],"subject_filter":["diterpene acids\n|||\nditerpene acids","1,3-dioxacycloalkanes\n|||\n1,3-dioxacycloalkanes","esters\n|||\nesters","chemical modification\n|||\nchemical modification","cytotoxicity\n|||\ncytotoxicity","web of science\n|||\nWeb of Science","дитерпеновые кислоты\n|||\nдитерпеновые кислоты","1,3-диоксациклоалканы\n|||\n1,3-диоксациклоалканы","сложные эфиры\n|||\nсложные эфиры","химическая модификация\n|||\nхимическая модификация","цитотоксичность\n|||\nцитотоксичность","вак\n|||\nВАК"],"dc.subject_mlt":["diterpene acids","1,3-dioxacycloalkanes","esters","chemical modification","cytotoxicity","Web of Science","дитерпеновые кислоты","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","цитотоксичность","ВАК"],"dc.subject":["diterpene acids","1,3-dioxacycloalkanes","esters","chemical modification","cytotoxicity","Web of Science","дитерпеновые кислоты","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","цитотоксичность","ВАК"],"dc.subject.en":["diterpene acids","1,3-dioxacycloalkanes","esters","chemical modification","cytotoxicity","Web of Science"],"dc.subject.ru_RU":["дитерпеновые кислоты","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","цитотоксичность","ВАК"],"title":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"title_keyword":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"title_ac":["синтез и цитотоксическая активность сложных эфировдитерпеновых кислот, содержащих циклоацетальный фрагмент\n|||\nСИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","synthesis and biological activity of diterpenic acids esters containing a cycloacetal fragment\n|||\nSYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title_sort":"СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","dc.title_hl":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title_mlt":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title_stored":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.title.ru_RU":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ"],"dc.title.en":["SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title.alternative":["SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT","СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ"],"dc.title.alternative.en":["SYNTHESIS AND BIOLOGICAL ACTIVITY OF DITERPENIC ACIDS ESTERS CONTAINING A CYCLOACETAL FRAGMENT"],"dc.title.alternative.ru_RU":["СИНТЕЗ И ЦИТОТОКСИЧЕСКАЯ АКТИВНОСТЬ СЛОЖНЫХ ЭФИРОВДИТЕРПЕНОВЫХ КИСЛОТ, СОДЕРЖАЩИХ ЦИКЛОАЦЕТАЛЬНЫЙ ФРАГМЕНТ"],"dc.type":["Article"],"dc.type.ru_RU":["Article"],"publication_grp":["123456789/6609"],"bi_2_dis_filter":["khusnutdinova, ns\n|||\nKhusnutdinova, NS","sultanova, rm\n|||\nSultanova, RM","раскильдина, г.з.\n|||\nРаскильдина, Г.З.","raskil'dina, gz\n|||\nRaskil'dina, GZ","sakhabutdinova, gn\n|||\nSakhabutdinova, GN","злотский, с.с.\n|||\nЗлотский, С.С.","мещерякова, с.а.\n|||\nМещерякова, С.А.","хуснутдинова, н.с.\n|||\nХуснутдинова, Н.С.","султанова, р.м.\n|||\nСултанова, Р.М.","сахабутдинова, г.н.\n|||\nСахабутдинова, Г.Н.","meshcheryakova, sa\n|||\nMeshcheryakova, SA","zlotsky, ss\n|||\nZlotsky, SS"],"bi_2_dis_partial":["Сахабутдинова, Г.Н.","Мещерякова, С.А.","Sakhabutdinova, GN","Meshcheryakova, SA","Раскильдина, Г.З.","Злотский, С.С.","Khusnutdinova, NS","Султанова, Р.М.","Zlotsky, SS","Sultanova, RM","Raskil'dina, GZ","Хуснутдинова, Н.С."],"bi_2_dis_value_filter":["Сахабутдинова, Г.Н.","Мещерякова, С.А.","Sakhabutdinova, GN","Meshcheryakova, SA","Раскильдина, Г.З.","Злотский, С.С.","Khusnutdinova, NS","Султанова, Р.М.","Zlotsky, SS","Sultanova, RM","Raskil'dina, GZ","Хуснутдинова, Н.С."],"bi_4_dis_filter":["esters\n|||\nesters","chemical modification\n|||\nchemical modification","цитотоксичность\n|||\nцитотоксичность","дитерпеновые кислоты\n|||\nдитерпеновые кислоты","1,3-диоксациклоалканы\n|||\n1,3-диоксациклоалканы","химическая модификация\n|||\nхимическая модификация","1,3-dioxacycloalkanes\n|||\n1,3-dioxacycloalkanes","diterpene acids\n|||\nditerpene acids","сложные эфиры\n|||\nсложные эфиры","cytotoxicity\n|||\ncytotoxicity","вак\n|||\nВАК","web of science\n|||\nWeb of Science"],"bi_4_dis_partial":["1,3-dioxacycloalkanes","Web of Science","цитотоксичность","ВАК","esters","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","diterpene acids","chemical modification","cytotoxicity","дитерпеновые кислоты"],"bi_4_dis_value_filter":["1,3-dioxacycloalkanes","Web of Science","цитотоксичность","ВАК","esters","1,3-диоксациклоалканы","сложные эфиры","химическая модификация","diterpene acids","chemical modification","cytotoxicity","дитерпеновые кислоты"],"bi_sort_1_sort":"синтез и цитотоксическая активность сложных эфировдитерпеновых кислот, содержащих циклоацетальный фрагмент","bi_sort_2_sort":"2022","bi_sort_3_sort":"2022-04-21T06:50:56Z","read":["g0"],"_version_":1745913669951160320},{"SolrIndexer.lastIndexed":"2023-01-23T05:09:34.379Z","search.uniqueid":"2-6393","search.resourcetype":2,"search.resourceid":6393,"handle":"123456789/7300","location":["m229","l684"],"location.comm":["229"],"location.coll":["684"],"withdrawn":"false","discoverable":"true","dc.abstract":["Lonicera caerulea L. and its subspecies Lonicera caerulea subsp. edulis (Turcz. ex Freyn) Hulten and Lonicera caerulea\nsubsp. altaica Pall. belong to the genus Lonicera L. family Caprifoliaceae Juss., they are valuable fruit plants that are used in\nmedicine, food industry, agriculture. The value of these species lies in the early ripening of fruits and a high content of vitamin\nC and other biologically active compounds.\nThe aim of the study was the qualitative and quantitative determination of the main groups of biologically active substances – organic acids and tannins, in the fruits of three species of the genus Lonicera from the collection of the South Ural\nBotanical Garden-Institute and the selection of the most promising species. For analysis, honeysuckle fruits were collected in the\nfull ripening phase and dried to an air-dry state. Phytochemical studies were carried out according to generally accepted methods.\nAs a result of the study, it was found that all the studied honeysuckle samples contain citric, malic, succinic, oxalic,\nascorbic acids, and tartaric acid in Lonicera caerulea subsp. edulis. According to the quantitative content of ascorbic acid and\nthe sum of organic acids, a species is distinguished in Lonicera caerulea subsp. edulis, whose fruits contain 174 and 1723 mg/100\ng respectively, and in Lonicera caerulea subsp. altaica and Lonicera caerulea their content is below. The analysis of fruits for\nthe content of tannins showed, that they are dominated by substances of condensed nature, which are based on catechism, and in\na larger amount they accumulate in Lonicera caerulea – 426 mg/100 g in a smaller amount – in Lonicera caerulea subsp. edulis\n– 171 mg/100 g.\nThe obtained data allow us to recommend the studied species of the genus Lonicera as a promising source of raw materials for the creation of medicinal plant products based on them, enriched with vitamins and other valuable biologically active\nsubstances on their basis."],"dc.abstract.en":["Lonicera caerulea L. and its subspecies Lonicera caerulea subsp. edulis (Turcz. ex Freyn) Hulten and Lonicera caerulea\nsubsp. altaica Pall. belong to the genus Lonicera L. family Caprifoliaceae Juss., they are valuable fruit plants that are used in\nmedicine, food industry, agriculture. The value of these species lies in the early ripening of fruits and a high content of vitamin\nC and other biologically active compounds.\nThe aim of the study was the qualitative and quantitative determination of the main groups of biologically active substances – organic acids and tannins, in the fruits of three species of the genus Lonicera from the collection of the South Ural\nBotanical Garden-Institute and the selection of the most promising species. For analysis, honeysuckle fruits were collected in the\nfull ripening phase and dried to an air-dry state. Phytochemical studies were carried out according to generally accepted methods.\nAs a result of the study, it was found that all the studied honeysuckle samples contain citric, malic, succinic, oxalic,\nascorbic acids, and tartaric acid in Lonicera caerulea subsp. edulis. According to the quantitative content of ascorbic acid and\nthe sum of organic acids, a species is distinguished in Lonicera caerulea subsp. edulis, whose fruits contain 174 and 1723 mg/100\ng respectively, and in Lonicera caerulea subsp. altaica and Lonicera caerulea their content is below. The analysis of fruits for\nthe content of tannins showed, that they are dominated by substances of condensed nature, which are based on catechism, and in\na larger amount they accumulate in Lonicera caerulea – 426 mg/100 g in a smaller amount – in Lonicera caerulea subsp. edulis\n– 171 mg/100 g.\nThe obtained data allow us to recommend the studied species of the genus Lonicera as a promising source of raw materials for the creation of medicinal plant products based on them, enriched with vitamins and other valuable biologically active\nsubstances on their basis."],"author":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г.","Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"author_keyword":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г.","Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"author_ac":["абдуллина, р.г.\n|||\nАбдуллина, Р.Г.","пупыкина, к.а.\n|||\nПупыкина, К.А.","баламетова, р.г.\n|||\nБаламетова, Р.Г.","abdullina, r.g.\n|||\nAbdullina, R.G.","pupykina, k.a.\n|||\nPupykina, K.A.","balametova, r.g.\n|||\nBalametova, R.G."],"author_filter":["абдуллина, р.г.\n|||\nАбдуллина, Р.Г.","пупыкина, к.а.\n|||\nПупыкина, К.А.","баламетова, р.г.\n|||\nБаламетова, Р.Г.","abdullina, r.g.\n|||\nAbdullina, R.G.","pupykina, k.a.\n|||\nPupykina, K.A.","balametova, r.g.\n|||\nBalametova, R.G."],"dc.contributor.author_hl":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г.","Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"dc.contributor.author_mlt":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г.","Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"dc.contributor.author":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г.","Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"dc.contributor.author_stored":["Абдуллина, Р.Г.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Пупыкина, К.А.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Баламетова, Р.Г.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","Abdullina, R.G.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Pupykina, K.A.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Balametova, R.G.\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.contributor.author.ru_RU":["Абдуллина, Р.Г.","Пупыкина, К.А.","Баламетова, Р.Г."],"dc.contributor.author.en":["Abdullina, R.G.","Pupykina, K.A.","Balametova, R.G."],"dc.date.accessioned_dt":"2023-01-23T05:07:20Z","dc.date.accessioned":["2023-01-23T05:07:20Z"],"dc.date.available":["2023-01-23T05:07:20Z"],"dateIssued":["2022-01-01"],"dateIssued_keyword":["2022-01-01","2022"],"dateIssued_ac":["2022-01-01\n|||\n2022-01-01","2022"],"dateIssued.year":[2022],"dateIssued.year_sort":"2022","dc.date.issued_dt":"2022-01-01T00:00:00Z","dc.date.issued":["2022-01-01"],"dc.date.issued_stored":["2022-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.description.abstract_hl":["Lonicera caerulea L и ее подвиды Lonicera caerulea subsp. edulis (Turcz. ex Freyn) Hulten и Lonicera caerulea subsp.\naltaica Pall. относятся к роду Lonicera L. семейства Caprifoliaceae Juss., являются ценными плодовыми растениями,\nкоторые используются в медицине, пищевой промышленности, сельском хозяйстве. Ценность этих видов заключается\nв раннем созревании плодов и высоком содержании витамина С и других биологически активных соединений.\nЦель исследования – качественное и количественное определение некоторых групп биологически активных веществ в плодах трех таксонов рода Lonicera коллекции Южно-Уральского ботанического сада-института и выделение\nнаиболее перспективных видов. Для анализов плоды жимолостей собирали в фазу полного созревания и высушивали\nдо воздушно-сухого состояния. Фитохимические исследования проводились по общепринятым методикам.\nВ результате исследования установлено, что во всех исследуемых образцах жимолости содержатся аскорбиновая, лимонная, яблочная, янтарная, щавелевая кислоты, а винная кислота обнаружена в Lonicera caerulea subsp. edulis.\nПо количественному содержанию аскорбиновой кислоты и суммы органических кислот выделяется Lonicera caerulea\nsubsp. edulis, в плодах которой содержится 174.8 мг/100 г и 1723 мг/100 г соответственно, а в Lonicera caerulea subsp.\naltaica и Lonicera caerulea их содержание ниже. Анализ плодов на содержание дубильных веществ показал, что в них\nпреобладают вещества конденсированной природы, в основе которых лежат катехины, и в большем количестве они\nнакапливаются в Lonicera caerulea – 426 мг/100 г, в меньшем – в Lonicera caerulea subsp. edulis – 171 мг/100 г. Полученные данные свидетельствуют о целесообразности их дальнейшего более детального изучения на содержание других\nгрупп биологически активных веществ в исследуемых образцах жимолостей"],"dc.description.abstract":["Lonicera caerulea L и ее подвиды Lonicera caerulea subsp. edulis (Turcz. ex Freyn) Hulten и Lonicera caerulea subsp.\naltaica Pall. относятся к роду Lonicera L. семейства Caprifoliaceae Juss., являются ценными плодовыми растениями,\nкоторые используются в медицине, пищевой промышленности, сельском хозяйстве. Ценность этих видов заключается\nв раннем созревании плодов и высоком содержании витамина С и других биологически активных соединений.\nЦель исследования – качественное и количественное определение некоторых групп биологически активных веществ в плодах трех таксонов рода Lonicera коллекции Южно-Уральского ботанического сада-института и выделение\nнаиболее перспективных видов. Для анализов плоды жимолостей собирали в фазу полного созревания и высушивали\nдо воздушно-сухого состояния. Фитохимические исследования проводились по общепринятым методикам.\nВ результате исследования установлено, что во всех исследуемых образцах жимолости содержатся аскорбиновая, лимонная, яблочная, янтарная, щавелевая кислоты, а винная кислота обнаружена в Lonicera caerulea subsp. edulis.\nПо количественному содержанию аскорбиновой кислоты и суммы органических кислот выделяется Lonicera caerulea\nsubsp. edulis, в плодах которой содержится 174.8 мг/100 г и 1723 мг/100 г соответственно, а в Lonicera caerulea subsp.\naltaica и Lonicera caerulea их содержание ниже. Анализ плодов на содержание дубильных веществ показал, что в них\nпреобладают вещества конденсированной природы, в основе которых лежат катехины, и в большем количестве они\nнакапливаются в Lonicera caerulea – 426 мг/100 г, в меньшем – в Lonicera caerulea subsp. edulis – 171 мг/100 г. Полученные данные свидетельствуют о целесообразности их дальнейшего более детального изучения на содержание других\nгрупп биологически активных веществ в исследуемых образцах жимолостей"],"dc.description.abstract.ru_RU":["Lonicera caerulea L и ее подвиды Lonicera caerulea subsp. edulis (Turcz. ex Freyn) Hulten и Lonicera caerulea subsp.\naltaica Pall. относятся к роду Lonicera L. семейства Caprifoliaceae Juss., являются ценными плодовыми растениями,\nкоторые используются в медицине, пищевой промышленности, сельском хозяйстве. Ценность этих видов заключается\nв раннем созревании плодов и высоком содержании витамина С и других биологически активных соединений.\nЦель исследования – качественное и количественное определение некоторых групп биологически активных веществ в плодах трех таксонов рода Lonicera коллекции Южно-Уральского ботанического сада-института и выделение\nнаиболее перспективных видов. Для анализов плоды жимолостей собирали в фазу полного созревания и высушивали\nдо воздушно-сухого состояния. Фитохимические исследования проводились по общепринятым методикам.\nВ результате исследования установлено, что во всех исследуемых образцах жимолости содержатся аскорбиновая, лимонная, яблочная, янтарная, щавелевая кислоты, а винная кислота обнаружена в Lonicera caerulea subsp. edulis.\nПо количественному содержанию аскорбиновой кислоты и суммы органических кислот выделяется Lonicera caerulea\nsubsp. edulis, в плодах которой содержится 174.8 мг/100 г и 1723 мг/100 г соответственно, а в Lonicera caerulea subsp.\naltaica и Lonicera caerulea их содержание ниже. Анализ плодов на содержание дубильных веществ показал, что в них\nпреобладают вещества конденсированной природы, в основе которых лежат катехины, и в большем количестве они\nнакапливаются в Lonicera caerulea – 426 мг/100 г, в меньшем – в Lonicera caerulea subsp. edulis – 171 мг/100 г. Полученные данные свидетельствуют о целесообразности их дальнейшего более детального изучения на содержание других\nгрупп биологически активных веществ в исследуемых образцах жимолостей"],"dc.doi":["10.14258/jcprm.20220310885"],"dc.identifier.issn":["1029-5151"],"dc.identifier.other":["УДК 633.88: 582.973: 581.6"],"dc.identifier.other.ru_RU":["УДК 633.88: 582.973: 581.6"],"dc.identifier.uri":["http://hdl.handle.net/123456789/7300"],"dc.relation.ispartofseries":["Khimiya Rastitel'nogo Syr'ya;№ 3"],"subject":["жимолость","Lonicera","плоды","аскорбиновая кислота","органические кислоты","дубильные вещества","химический состав","Scopus","honeysuckle","Lonicera","fruits","ascorbic acid","organic acids","tannins","chemical comp"],"subject_keyword":["жимолость","жимолость","Lonicera","Lonicera","плоды","плоды","аскорбиновая кислота","аскорбиновая кислота","органические кислоты","органические кислоты","дубильные вещества","дубильные вещества","химический состав","химический состав","Scopus","Scopus","honeysuckle","honeysuckle","Lonicera","Lonicera","fruits","fruits","ascorbic acid","ascorbic acid","organic acids","organic acids","tannins","tannins","chemical comp","chemical comp"],"subject_ac":["жимолость\n|||\nжимолость","lonicera\n|||\nLonicera","плоды\n|||\nплоды","аскорбиновая кислота\n|||\nаскорбиновая кислота","органические кислоты\n|||\nорганические кислоты","дубильные вещества\n|||\nдубильные вещества","химический состав\n|||\nхимический состав","scopus\n|||\nScopus","honeysuckle\n|||\nhoneysuckle","lonicera\n|||\nLonicera","fruits\n|||\nfruits","ascorbic acid\n|||\nascorbic acid","organic acids\n|||\norganic acids","tannins\n|||\ntannins","chemical comp\n|||\nchemical comp"],"subject_tax_0_filter":["жимолость\n|||\nжимолость","lonicera\n|||\nLonicera","плоды\n|||\nплоды","аскорбиновая кислота\n|||\nаскорбиновая кислота","органические кислоты\n|||\nорганические кислоты","дубильные вещества\n|||\nдубильные вещества","химический состав\n|||\nхимический состав","scopus\n|||\nScopus","honeysuckle\n|||\nhoneysuckle","lonicera\n|||\nLonicera","fruits\n|||\nfruits","ascorbic acid\n|||\nascorbic acid","organic acids\n|||\norganic acids","tannins\n|||\ntannins","chemical comp\n|||\nchemical comp"],"subject_filter":["жимолость\n|||\nжимолость","lonicera\n|||\nLonicera","плоды\n|||\nплоды","аскорбиновая кислота\n|||\nаскорбиновая кислота","органические кислоты\n|||\nорганические кислоты","дубильные вещества\n|||\nдубильные вещества","химический состав\n|||\nхимический состав","scopus\n|||\nScopus","honeysuckle\n|||\nhoneysuckle","lonicera\n|||\nLonicera","fruits\n|||\nfruits","ascorbic acid\n|||\nascorbic acid","organic acids\n|||\norganic acids","tannins\n|||\ntannins","chemical comp\n|||\nchemical comp"],"dc.subject_mlt":["жимолость","Lonicera","плоды","аскорбиновая кислота","органические кислоты","дубильные вещества","химический состав","Scopus","honeysuckle","Lonicera","fruits","ascorbic acid","organic acids","tannins","chemical comp"],"dc.subject":["жимолость","Lonicera","плоды","аскорбиновая кислота","органические кислоты","дубильные вещества","химический состав","Scopus","honeysuckle","Lonicera","fruits","ascorbic acid","organic acids","tannins","chemical comp"],"dc.subject.ru_RU":["жимолость","Lonicera","плоды","аскорбиновая кислота","органические кислоты","дубильные вещества","химический состав","Scopus","honeysuckle","Lonicera","fruits","ascorbic acid","organic acids","tannins","chemical comp"],"title":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ",""],"title_keyword":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ",""],"title_ac":["биохимический состав плодов lonicera caerulea l. и ее подвидов при интродукции в условиях башкирского предуралья\n|||\nБИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ","\n|||\n"],"dc.title_sort":"БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ","dc.title_hl":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ",""],"dc.title_mlt":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ",""],"dc.title":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ",""],"dc.title_stored":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru_RU","\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.title.ru_RU":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ"],"dc.title.alternative":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ","BIOCHEMICAL COMPOSITION OF FRUITS OF LONICERA CAERULEA L. AND ITS SUBSPECIES DURING INTRODUCTION IN THE CONDITIONS OF THE BASHKIR URALS"],"dc.title.alternative.ru_RU":["БИОХИМИЧЕСКИЙ СОСТАВ ПЛОДОВ LONICERA CAERULEA L. И ЕЕ ПОДВИДОВ ПРИ ИНТРОДУКЦИИ В УСЛОВИЯХ БАШКИРСКОГО ПРЕДУРАЛЬЯ","BIOCHEMICAL COMPOSITION OF FRUITS OF LONICERA CAERULEA L. AND ITS SUBSPECIES DURING INTRODUCTION IN THE CONDITIONS OF THE BASHKIR URALS"],"dc.type":["Article"],"dc.type.ru_RU":["Article"],"publication_grp":["123456789/7300"],"bi_2_dis_filter":["баламетова, р.г.\n|||\nБаламетова, Р.Г.","abdullina, r.g.\n|||\nAbdullina, R.G.","pupykina, k.a.\n|||\nPupykina, K.A.","balametova, r.g.\n|||\nBalametova, R.G.","пупыкина, к.а.\n|||\nПупыкина, К.А.","абдуллина, р.г.\n|||\nАбдуллина, Р.Г."],"bi_2_dis_partial":["Abdullina, R.G.","Пупыкина, К.А.","Balametova, R.G.","Баламетова, Р.Г.","Pupykina, K.A.","Абдуллина, Р.Г."],"bi_2_dis_value_filter":["Abdullina, R.G.","Пупыкина, К.А.","Balametova, R.G.","Баламетова, Р.Г.","Pupykina, K.A.","Абдуллина, Р.Г."],"bi_4_dis_filter":["аскорбиновая кислота\n|||\nаскорбиновая кислота","дубильные вещества\n|||\nдубильные вещества","tannins\n|||\ntannins","fruits\n|||\nfruits","honeysuckle\n|||\nhoneysuckle","scopus\n|||\nScopus","chemical comp\n|||\nchemical comp","organic acids\n|||\norganic acids","плоды\n|||\nплоды","органические кислоты\n|||\nорганические кислоты","ascorbic acid\n|||\nascorbic acid","жимолость\n|||\nжимолость","химический состав\n|||\nхимический состав","lonicera\n|||\nLonicera"],"bi_4_dis_partial":["аскорбиновая кислота","ascorbic acid","Scopus","chemical comp","жимолость","дубильные вещества","плоды","organic acids","органические кислоты","химический состав","honeysuckle","fruits","Lonicera","tannins"],"bi_4_dis_value_filter":["аскорбиновая кислота","ascorbic acid","Scopus","chemical comp","жимолость","дубильные вещества","плоды","organic acids","органические кислоты","химический состав","honeysuckle","fruits","Lonicera","tannins"],"bi_sort_1_sort":"биохимический состав плодов lonicera caerulea l. и ее подвидов при интродукции в условиях башкирского предуралья","bi_sort_2_sort":"2022","bi_sort_3_sort":"2023-01-23T05:07:20Z","read":["g0"],"_version_":1755788685488422912},{"SolrIndexer.lastIndexed":"2021-06-09T06:09:15.772Z","search.uniqueid":"2-4193","search.resourcetype":2,"search.resourceid":4193,"handle":"123456789/5098","location":["m195","l691"],"location.comm":["195"],"location.coll":["691"],"withdrawn":"false","discoverable":"true","dc.abstract":["Organs transplantation is a method of choice in the treatment of many acute and chronic diseases in their final stage, as well as in some cases of primary malignant neoplasms. With the increase in the number of operations performed, data on a variety of complications of these interventions, including neurological ones, began to accumulate.Patients, who underwent transplantation of internal organs, are forced to be on immunosuppressive therapy. It includes the appointment of glucocorticoids (prednisolone or methylprednisolone), inhibitors of calcineurin (cyclosporine A or tacrolimus), inhibitors of inosine monophosphate dehydrogenase (mycophenolate mofetil or mycophenolic acid). The severity of neurological disorders can range from mild (headache, dizziness, paresthesia, dysesthesia, tremor, sleep disturbance, photophobia) to extremely severe manifestations (mental confusion, seizures, cortical blindness, encephalopathy and coma). Typically, these symptoms occur soon after transplantation. Most likely, the neurotoxic effect of drugs develops against the background of intensive therapy with immunosuppressants and has a significant impact on the survival and life quality of patients.","Трансплантация внутренних органов является методом выбора в лечении многих острых и хронических заболеваний в их конечной стадии, а также в некоторых случаях первичных злокачественных новообразований. С увеличением количества выполняемых операций стали накапливаться сведения о множестве различных осложнений данных вмешательств, в том числе и неврологических.Пациенты, перенесшие трансплантацию внутренних органов, вынуждены находиться на иммуносупрессивной терапии. Она включает в себя назначение глюкокортикоидов (преднизолон или метилпреднизолон), ингибиторов кальциневрина(циклоспорин А или такролимус), ингибиторов инозинмонофосфатдегидрогеназы (мофетил микофенолат или микофеноло-вая кислота). Степень тяжести неврологических расстройств может варьировать от умеренных (головная боль, головокружение, парестезии, дизестезии, тремор, нарушение сна, светобоязнь) до крайне тяжелых проявлений (спутанность сознания, судороги, корковая слепота, энцефалопатия и кома). Как правило, эти симптомы возникают вскоре после трансплантации. Вероятнее всего, нейротоксичное действие препаратов развивается на фоне интенсивной терапии иммунодепрессантами и оказывает значительное влияние на выживаемость и качество жизни пациентов."],"dc.abstract.en":["Organs transplantation is a method of choice in the treatment of many acute and chronic diseases in their final stage, as well as in some cases of primary malignant neoplasms. With the increase in the number of operations performed, data on a variety of complications of these interventions, including neurological ones, began to accumulate.Patients, who underwent transplantation of internal organs, are forced to be on immunosuppressive therapy. It includes the appointment of glucocorticoids (prednisolone or methylprednisolone), inhibitors of calcineurin (cyclosporine A or tacrolimus), inhibitors of inosine monophosphate dehydrogenase (mycophenolate mofetil or mycophenolic acid). The severity of neurological disorders can range from mild (headache, dizziness, paresthesia, dysesthesia, tremor, sleep disturbance, photophobia) to extremely severe manifestations (mental confusion, seizures, cortical blindness, encephalopathy and coma). Typically, these symptoms occur soon after transplantation. Most likely, the neurotoxic effect of drugs develops against the background of intensive therapy with immunosuppressants and has a significant impact on the survival and life quality of patients."],"dc.abstract.ru":["Трансплантация внутренних органов является методом выбора в лечении многих острых и хронических заболеваний в их конечной стадии, а также в некоторых случаях первичных злокачественных новообразований. С увеличением количества выполняемых операций стали накапливаться сведения о множестве различных осложнений данных вмешательств, в том числе и неврологических.Пациенты, перенесшие трансплантацию внутренних органов, вынуждены находиться на иммуносупрессивной терапии. Она включает в себя назначение глюкокортикоидов (преднизолон или метилпреднизолон), ингибиторов кальциневрина(циклоспорин А или такролимус), ингибиторов инозинмонофосфатдегидрогеназы (мофетил микофенолат или микофеноло-вая кислота). Степень тяжести неврологических расстройств может варьировать от умеренных (головная боль, головокружение, парестезии, дизестезии, тремор, нарушение сна, светобоязнь) до крайне тяжелых проявлений (спутанность сознания, судороги, корковая слепота, энцефалопатия и кома). Как правило, эти симптомы возникают вскоре после трансплантации. Вероятнее всего, нейротоксичное действие препаратов развивается на фоне интенсивной терапии иммунодепрессантами и оказывает значительное влияние на выживаемость и качество жизни пациентов."],"dc.author.affiliation":["ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России","ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России"],"dc.author.affiliation.ru":["ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России","ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России"],"dc.author.full":["Э. Р. Хасанова | ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России","E. R. Khasanova |","К. З. Бахтиярова | ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России","K. Z. Bakhtiyarova |"],"dc.author.full.ru":["Э. Р. Хасанова | ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России","К. З. Бахтиярова | ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России"],"dc.author.full.en":["E. R. Khasanova |","K. Z. Bakhtiyarova |"],"author":["Э. Р. Хасанова","E. R. Khasanova","К. З. Бахтиярова","K. Z. Bakhtiyarova"],"author_keyword":["Э. Р. Хасанова","E. R. Khasanova","К. З. Бахтиярова","K. Z. Bakhtiyarova"],"author_ac":["э. р. хасанова\n|||\nЭ. Р. Хасанова","e. r. khasanova\n|||\nE. R. Khasanova","к. з. бахтиярова\n|||\nК. З. Бахтиярова","k. z. bakhtiyarova\n|||\nK. Z. Bakhtiyarova"],"author_filter":["э. р. хасанова\n|||\nЭ. Р. Хасанова","e. r. khasanova\n|||\nE. R. Khasanova","к. з. бахтиярова\n|||\nК. З. Бахтиярова","k. z. bakhtiyarova\n|||\nK. Z. Bakhtiyarova"],"dc.author.name":["Э. Р. Хасанова","E. R. Khasanova","К. З. Бахтиярова","K. Z. Bakhtiyarova"],"dc.author.name.ru":["Э. Р. Хасанова","К. З. Бахтиярова"],"dc.author.name.en":["E. R. Khasanova","K. Z. Bakhtiyarova"],"dc.authors":["{\"authors\": [{\"ru\": {\"affiliation\": \"\\u0424\\u0413\\u0411\\u041e\\u0423 \\u0412\\u041e \\u00ab\\u0411\\u0430\\u0448\\u043a\\u0438\\u0440\\u0441\\u043a\\u0438\\u0439 \\u0433\\u043e\\u0441\\u0443\\u0434\\u0430\\u0440\\u0441\\u0442\\u0432\\u0435\\u043d\\u043d\\u044b\\u0439 \\u043c\\u0435\\u0434\\u0438\\u0446\\u0438\\u043d\\u0441\\u043a\\u0438\\u0439 \\u0443\\u043d\\u0438\\u0432\\u0435\\u0440\\u0441\\u0438\\u0442\\u0435\\u0442\\u00bb \\u041c\\u0438\\u043d\\u0437\\u0434\\u0440\\u0430\\u0432\\u0430 \\u0420\\u043e\\u0441\\u0441\\u0438\\u0438\", \"full_name\": \"\\u042d. \\u0420. \\u0425\\u0430\\u0441\\u0430\\u043d\\u043e\\u0432\\u0430\"}, \"en\": {\"affiliation\": \"\", \"full_name\": \"E. R. Khasanova\"}}, {\"ru\": {\"affiliation\": \"\\u0424\\u0413\\u0411\\u041e\\u0423 \\u0412\\u041e \\u00ab\\u0411\\u0430\\u0448\\u043a\\u0438\\u0440\\u0441\\u043a\\u0438\\u0439 \\u0433\\u043e\\u0441\\u0443\\u0434\\u0430\\u0440\\u0441\\u0442\\u0432\\u0435\\u043d\\u043d\\u044b\\u0439 \\u043c\\u0435\\u0434\\u0438\\u0446\\u0438\\u043d\\u0441\\u043a\\u0438\\u0439 \\u0443\\u043d\\u0438\\u0432\\u0435\\u0440\\u0441\\u0438\\u0442\\u0435\\u0442\\u00bb \\u041c\\u0438\\u043d\\u0437\\u0434\\u0440\\u0430\\u0432\\u0430 \\u0420\\u043e\\u0441\\u0441\\u0438\\u0438\", \"full_name\": \"\\u041a. \\u0417. \\u0411\\u0430\\u0445\\u0442\\u0438\\u044f\\u0440\\u043e\\u0432\\u0430\"}, \"en\": {\"affiliation\": \"\", \"full_name\": \"K. Z. Bakhtiyarova\"}}]}"],"dc.citation":["Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity / B. Appignani [et al.] // AJR Am. J. Roentgenol. - 1996. - Vol. 166. - P. 683-688","Государственный реестр лекарственных средств. Официальное издание: в 2 т.- М.: Медицинский совет, 2009. - Т.2, ч.1. - 568 с.; ч.2. - 560 с","Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole / S. Bayers [et al.] // J. Am. Acad. Dermatol. - 2013. - Vol. 69. - P. e177-8","Interaction between tacrolimus and nefazodone in a stable renal transplant recipient / A. Olyaei [et al.] // Pharmacotherapy. - 1998. - Vol. 18. - P. 1356-1359","Wijdicks, E.F. Neurotoxicity of immunosuppressive drug / E.F. Wijdicks // Liver Transpl. - 2001. - Vol. 7. - P. 937-942","Ташенова, А. Транспортная система гликопротеина-Рифармакокинетика лекарственных средств / А. Ташенова // Биомедицина. - 2010. - № 4. - С. 24-32","Neurologic complications of FK 506 / B. Eidelman [et al.] // Transplant. Proc. - 1991. - Vol. 23. - P. 3175-3178","FK506-induced neurotoxicity in liver transplantation / E. Wijdicks [et al.] // Ann. Neurol. - 1994. - Vol. 35. - P. 498-501","Sensorimotor neuropathy resembling CIDP in patients receiving FK506 / J. Wilson [et al.] // Muscle Nerve. - 1994. - Vol. 17. - P. 528-532","Peripheral neurotoxicity with tacrolimus / R. Ayres [et al.] // Lancet - 1994. - Vol. 343. - P. 862-3","Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation / B. Forgacs [et al.] // Transplant. Proc. - 2005. - Vol. 37. - P. 1912-14","Пизова, Н. Синдром обратимой задней лейкоэнцефалопатии при системной красной волчанке / Н. Пизова // Неврологический журнал. - 2014. - №19 (6). - С. 44-49","Dillon, W.P. The reversible posterior cerebral edema syndrome [comment] / W.P. Dillon, H. Rowley // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 591","Expressive dysphasia possibly related to FK506 in two liver transplant recipients / J. Reyes [et al.] // Transplantation - 1990. - Vol. 50. - P. 1043-1045","Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation / L. Shutter [et al.] // Neurology - 1993. - Vol. 43. - P. 2417-2418","MR imaging of reversible cyclosporin A-induced neurotoxicity / C. Truwit [et al.] // AJNR Am. J. Neuroradiol. - 1991. - Vol. 12. - P. 651-659","A reversible leukoencephalopathy syndrome / J. Hinchey [et al.] // N. Engl. J. Med. - 1996. - Vol. 334. - P. 494-500","Albayram, S. MR imaging findings of cortical blindness following cerebral angiography: is this entity related to posterior reversible leukoencephalopathy? / S. Albayram, H. Ozer // Am. J. Neuroradiol. - 2005. - Vol. 26. - P. 193","Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler [et al.] // Am. J. Neuroradiol. - 2002. - Vol. 23. - P. 833-7","Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay / T. Kinoshita [et al.] // Clin. Imag. - 2003. - Vol. 27. - P. 307-15","Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping / K. Ahn [et al.] // Neuroradiology. - 2004. - Vol. 46. - P. 978-83","Immunosuppression-induced leukoencephalopathy from tacrolimus / S. Small [et al.] // Ann. Neurol. - 1996. - Vol. 40. - P. 575-580","Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome / Y. Ito [et al.] // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 415-417","Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI / H. Ay [et al.] // Neurology. - 1998. - Vol. 15. - P. 1369-1376","Transient neurotoxicity associated with FK506: MR findings / N. Tomura [et al.] // J. Comput. Assist. Tomogr. - 1998. - Vol. 22. - P. 505-507","Neurologic complications in adult living donor liver transplant recipients / B. Kim [et al.] // Clin. Transplant. - 2007. - Vol. 21, № 4. - P. 544-547","Adams, R. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients / R. Adams, M. Victor, E. Mancall // AMA Arch. Neurol. Psychiatry. - 1959. - Vol. 81. - P. 154-172","Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus / T. Starzl [et al.] // Ann. Surg. - 1978. - Vol. 187, № 3. - P. 236-240","Brown, W.D. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis / W. D. Brown // Curr. Opin.Neurol. - 2000. - Vol. 13. - P. 691-697","Newell, K.L. Central pontine myelinolysis at autopsy; a twelve year retrospective analysis / K.L. Newell, B.K. Kleinschmidt-DeMasters // J. Neurol. Sci. - 1996. - Vol. 142. - P. 1394-1399","Central pontine and extrapontine myelinolysis: a rare and fatal complication after liver transplantation / P. Cascales Campos [et al.] // Transplant. Proc. - 2011. - Vol. 43, № 6. - P. 2237-2238","Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation / K. Fukazawa [et al.] // Ann. Transplant. - 2011. - Vol. 16, № 3. - P. 139-142","Neurological complications of liver cirrhosis and liver transplant / G. Ardizzone [et al.] // Transplant. Proc. - 2006. - Vol. 38, № 3. - P. 789-792","Price, B.H. Behavioral manifestations of central pontine myelinolysis / B.H. Price, M.M. Mesulam // Arch. Neurol. - 1987. - Vol. 44. - P. 671-673","Soupart, A. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia / A. Soupart, M. Ngassa, G. Decaux // Clin. Nephrol. - 1999. - Vol. 51. - P. 383-386","Harris, C.P. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? / C.P. Harris, J.J. Townsend, J.R. Baringer // J. Neurol. Neurosurg. Psychiatry. - 1993. - Vol. 56. - P. 626-632","Mittal, R. Management of hyponatraemia / R. Mittal, H. Sheftel, Y Demssie // Br. J. Hosp. Med. (Lond). - 2011. - Vol. 72, № 2. - P. 22-25","Possible causes of central pontine myelinolysis after liver transplantation / J. Yu [et al.] //World J. Gastroenterol. - 2004. - Vol. 10, № 17. - P. 2540-2543","Clinical and radiologic correlations of central pontine myelinolysis syndrome / J. Graff-Radford [et al.] // Mayo Clin. Proc. - 2011. - Vol. 86, № 11. - P. 1063-1067","Мельничук, П.В. Инфекционные и паразитарные заболевания нервной системы. Абсцесс мозга // Болезни нервной системы/ под ред. Н.Н. Яхно / П.В. Мельничук, Д.Р. Штульман. - М.: МЕДИЦИНА, 2007. - Т. 1. - 340 с","Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression / R. Selby [et al.] // Arch. Surg. - 1997. - Vol. 132. - P. 304-310","Baddley, J.W. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features / J. Baddley, D. Salzman, P. Pappas // Clin. Transplant. - 2002. - Vol. 16. - P. 419-424","Pseudallscheria boydii (Anamorph Scedosporium apiospermum) infection in organ transplant recipients in a tertiary medical center and review of the literature / B. Castiglioni [et al.] // Medicine - 2002. - Vol. 81. - P. 333-348","Disseminated scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report / P. Rogasi [et al.] // Transplant. Proc. -2007. - Vol. 39. - P. 2033-2035","Disseminated pseudallescheria boydii (scedosporium apiospermum) infection in a renal transplant patient / E. Campagnaro [et al.] // Transpl. Infect. Dis. - 2002. - Vol. 4. - P. 207-211","Walker, D.H. Disseminated petriellidosis (allescheriasis) / D. Walker, T. Adamec, M. Krigman // Arch. Pathol. Lab. Med. - 1978. - Vol. 102. - P. 158-160","Bilateral pseudallescheria boydii endophthalmitis in an immunocompromised patient / J. Caya [et al.] // Wis. Med. J. - 1988. - Vol. 87. - P. 11-14","Nesky, M.A. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis / M. Nesky, E. McDougal, J. Peacock // Clin. Infect. Dis. - 2000. - Vol. 31. - P. 673-677","Lavarde, V. Brain abscess due to pseudallescheria boydii in a renal transplant patient / V. Lavarde, F. Traore, D. Farge // Bull. Soc. Fr. Mycol. Medical. - 1989. - Vol. 18. - P. 149-152","Infection due to scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by pseudallescheria boydii / M. Montejo [et al.] // Sc. Mycoses. - 2002. - Vol. 45. - P. 418-427","Pseudallescheria boydii brain abscess in a renal transplant recipient: first case report in southeast Asia / B. Satirapoj [et al.] // Transplant. Proc. - 2008. - Vol. 40. - P. 2425-2427","Treatment of a brain abscess caused by scedosporium apiospermum and phaeoacremonium parasiticum in a renal transplant recipient / N. Larbcharoensub [et al.] // Southeast Asian J. Trop. Med. Public Health - 2013. - Vol. 44. - P. 484-489","Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation / J. Suzuki [et al.] // Transpl. Infect. Dis. - 2012. - Vol. 14, № 4. - P. 7-12. doi: 10.1111/j.1399-3062.2012.00720.x","Herpesvirus hominis type 2 meningoencephalitis following renal transplantation / CC. Jr. Linnemann [et al.] // Am. J. Med. - 1976. - Vol. 61, № 5. - P. 703-708","Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem celltransplant recipients / K. Fujimaki [et al.] // Int. J. Hematol. - 2006. - Vol. 84, № 5. - P. 432-437","Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity / B. Appignani [et al.] // AJR Am. J. Roentgenol. - 1996. - Vol. 166. - P. 683-688","Государственный реестр лекарственных средств. Официальное издание: в 2 т.- М.: Медицинский совет, 2009. - Т.2, ч.1. - 568 с.; ч.2. - 560 с","Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole / S. Bayers [et al.] // J. Am. Acad. Dermatol. - 2013. - Vol. 69. - P. e177-8","Interaction between tacrolimus and nefazodone in a stable renal transplant recipient / A. Olyaei [et al.] // Pharmacotherapy. - 1998. - Vol. 18. - P. 1356-1359","Wijdicks, E.F. Neurotoxicity of immunosuppressive drug / E.F. Wijdicks // Liver Transpl. - 2001. - Vol. 7. - P. 937-942","Ташенова, А. Транспортная система гликопротеина-Рифармакокинетика лекарственных средств / А. Ташенова // Биомедицина. - 2010. - № 4. - С. 24-32","Neurologic complications of FK 506 / B. Eidelman [et al.] // Transplant. Proc. - 1991. - Vol. 23. - P. 3175-3178","FK506-induced neurotoxicity in liver transplantation / E. Wijdicks [et al.] // Ann. Neurol. - 1994. - Vol. 35. - P. 498-501","Sensorimotor neuropathy resembling CIDP in patients receiving FK506 / J. Wilson [et al.] // Muscle Nerve. - 1994. - Vol. 17. - P. 528-532","Peripheral neurotoxicity with tacrolimus / R. Ayres [et al.] // Lancet - 1994. - Vol. 343. - P. 862-3","Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation / B. Forgacs [et al.] // Transplant. Proc. - 2005. - Vol. 37. - P. 1912-14","Пизова, Н. Синдром обратимой задней лейкоэнцефалопатии при системной красной волчанке / Н. Пизова // Неврологический журнал. - 2014. - №19 (6). - С. 44-49","Dillon, W.P. The reversible posterior cerebral edema syndrome [comment] / W.P. Dillon, H. Rowley // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 591","Expressive dysphasia possibly related to FK506 in two liver transplant recipients / J. Reyes [et al.] // Transplantation - 1990. - Vol. 50. - P. 1043-1045","Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation / L. Shutter [et al.] // Neurology - 1993. - Vol. 43. - P. 2417-2418","MR imaging of reversible cyclosporin A-induced neurotoxicity / C. Truwit [et al.] // AJNR Am. J. Neuroradiol. - 1991. - Vol. 12. - P. 651-659","A reversible leukoencephalopathy syndrome / J. Hinchey [et al.] // N. Engl. J. Med. - 1996. - Vol. 334. - P. 494-500","Albayram, S. MR imaging findings of cortical blindness following cerebral angiography: is this entity related to posterior reversible leukoencephalopathy? / S. Albayram, H. Ozer // Am. J. Neuroradiol. - 2005. - Vol. 26. - P. 193","Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler [et al.] // Am. J. Neuroradiol. - 2002. - Vol. 23. - P. 833-7","Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay / T. Kinoshita [et al.] // Clin. Imag. - 2003. - Vol. 27. - P. 307-15","Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping / K. Ahn [et al.] // Neuroradiology. - 2004. - Vol. 46. - P. 978-83","Immunosuppression-induced leukoencephalopathy from tacrolimus / S. Small [et al.] // Ann. Neurol. - 1996. - Vol. 40. - P. 575-580","Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome / Y. Ito [et al.] // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 415-417","Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI / H. Ay [et al.] // Neurology. - 1998. - Vol. 15. - P. 1369-1376","Transient neurotoxicity associated with FK506: MR findings / N. Tomura [et al.] // J. Comput. Assist. Tomogr. - 1998. - Vol. 22. - P. 505-507","Neurologic complications in adult living donor liver transplant recipients / B. Kim [et al.] // Clin. Transplant. - 2007. - Vol. 21, № 4. - P. 544-547","Adams, R. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients / R. Adams, M. Victor, E. Mancall // AMA Arch. Neurol. Psychiatry. - 1959. - Vol. 81. - P. 154-172","Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus / T. Starzl [et al.] // Ann. Surg. - 1978. - Vol. 187, № 3. - P. 236-240","Brown, W.D. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis / W. D. Brown // Curr. Opin.Neurol. - 2000. - Vol. 13. - P. 691-697","Newell, K.L. Central pontine myelinolysis at autopsy; a twelve year retrospective analysis / K.L. Newell, B.K. Kleinschmidt-DeMasters // J. Neurol. Sci. - 1996. - Vol. 142. - P. 1394-1399","Central pontine and extrapontine myelinolysis: a rare and fatal complication after liver transplantation / P. Cascales Campos [et al.] // Transplant. Proc. - 2011. - Vol. 43, № 6. - P. 2237-2238","Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation / K. Fukazawa [et al.] // Ann. Transplant. - 2011. - Vol. 16, № 3. - P. 139-142","Neurological complications of liver cirrhosis and liver transplant / G. Ardizzone [et al.] // Transplant. Proc. - 2006. - Vol. 38, № 3. - P. 789-792","Price, B.H. Behavioral manifestations of central pontine myelinolysis / B.H. Price, M.M. Mesulam // Arch. Neurol. - 1987. - Vol. 44. - P. 671-673","Soupart, A. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia / A. Soupart, M. Ngassa, G. Decaux // Clin. Nephrol. - 1999. - Vol. 51. - P. 383-386","Harris, C.P. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? / C.P. Harris, J.J. Townsend, J.R. Baringer // J. Neurol. Neurosurg. Psychiatry. - 1993. - Vol. 56. - P. 626-632","Mittal, R. Management of hyponatraemia / R. Mittal, H. Sheftel, Y Demssie // Br. J. Hosp. Med. (Lond). - 2011. - Vol. 72, № 2. - P. 22-25","Possible causes of central pontine myelinolysis after liver transplantation / J. Yu [et al.] //World J. Gastroenterol. - 2004. - Vol. 10, № 17. - P. 2540-2543","Clinical and radiologic correlations of central pontine myelinolysis syndrome / J. Graff-Radford [et al.] // Mayo Clin. Proc. - 2011. - Vol. 86, № 11. - P. 1063-1067","Мельничук, П.В. Инфекционные и паразитарные заболевания нервной системы. Абсцесс мозга // Болезни нервной системы/ под ред. Н.Н. Яхно / П.В. Мельничук, Д.Р. Штульман. - М.: МЕДИЦИНА, 2007. - Т. 1. - 340 с","Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression / R. Selby [et al.] // Arch. Surg. - 1997. - Vol. 132. - P. 304-310","Baddley, J.W. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features / J. Baddley, D. Salzman, P. Pappas // Clin. Transplant. - 2002. - Vol. 16. - P. 419-424","Pseudallscheria boydii (Anamorph Scedosporium apiospermum) infection in organ transplant recipients in a tertiary medical center and review of the literature / B. Castiglioni [et al.] // Medicine - 2002. - Vol. 81. - P. 333-348","Disseminated scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report / P. Rogasi [et al.] // Transplant. Proc. -2007. - Vol. 39. - P. 2033-2035","Disseminated pseudallescheria boydii (scedosporium apiospermum) infection in a renal transplant patient / E. Campagnaro [et al.] // Transpl. Infect. Dis. - 2002. - Vol. 4. - P. 207-211","Walker, D.H. Disseminated petriellidosis (allescheriasis) / D. Walker, T. Adamec, M. Krigman // Arch. Pathol. Lab. Med. - 1978. - Vol. 102. - P. 158-160","Bilateral pseudallescheria boydii endophthalmitis in an immunocompromised patient / J. Caya [et al.] // Wis. Med. J. - 1988. - Vol. 87. - P. 11-14","Nesky, M.A. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis / M. Nesky, E. McDougal, J. Peacock // Clin. Infect. Dis. - 2000. - Vol. 31. - P. 673-677","Lavarde, V. Brain abscess due to pseudallescheria boydii in a renal transplant patient / V. Lavarde, F. Traore, D. Farge // Bull. Soc. Fr. Mycol. Medical. - 1989. - Vol. 18. - P. 149-152","Infection due to scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by pseudallescheria boydii / M. Montejo [et al.] // Sc. Mycoses. - 2002. - Vol. 45. - P. 418-427","Pseudallescheria boydii brain abscess in a renal transplant recipient: first case report in southeast Asia / B. Satirapoj [et al.] // Transplant. Proc. - 2008. - Vol. 40. - P. 2425-2427","Treatment of a brain abscess caused by scedosporium apiospermum and phaeoacremonium parasiticum in a renal transplant recipient / N. Larbcharoensub [et al.] // Southeast Asian J. Trop. Med. Public Health - 2013. - Vol. 44. - P. 484-489","Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation / J. Suzuki [et al.] // Transpl. Infect. Dis. - 2012. - Vol. 14, № 4. - P. 7-12. doi: 10.1111/j.1399-3062.2012.00720.x","Herpesvirus hominis type 2 meningoencephalitis following renal transplantation / CC. Jr. Linnemann [et al.] // Am. J. Med. - 1976. - Vol. 61, № 5. - P. 703-708","Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem celltransplant recipients / K. Fujimaki [et al.] // Int. J. Hematol. - 2006. - Vol. 84, № 5. - P. 432-437"],"dc.citation.ru":["Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity / B. Appignani [et al.] // AJR Am. J. Roentgenol. - 1996. - Vol. 166. - P. 683-688","Государственный реестр лекарственных средств. Официальное издание: в 2 т.- М.: Медицинский совет, 2009. - Т.2, ч.1. - 568 с.; ч.2. - 560 с","Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole / S. Bayers [et al.] // J. Am. Acad. Dermatol. - 2013. - Vol. 69. - P. e177-8","Interaction between tacrolimus and nefazodone in a stable renal transplant recipient / A. Olyaei [et al.] // Pharmacotherapy. - 1998. - Vol. 18. - P. 1356-1359","Wijdicks, E.F. Neurotoxicity of immunosuppressive drug / E.F. Wijdicks // Liver Transpl. - 2001. - Vol. 7. - P. 937-942","Ташенова, А. Транспортная система гликопротеина-Рифармакокинетика лекарственных средств / А. Ташенова // Биомедицина. - 2010. - № 4. - С. 24-32","Neurologic complications of FK 506 / B. Eidelman [et al.] // Transplant. Proc. - 1991. - Vol. 23. - P. 3175-3178","FK506-induced neurotoxicity in liver transplantation / E. Wijdicks [et al.] // Ann. Neurol. - 1994. - Vol. 35. - P. 498-501","Sensorimotor neuropathy resembling CIDP in patients receiving FK506 / J. Wilson [et al.] // Muscle Nerve. - 1994. - Vol. 17. - P. 528-532","Peripheral neurotoxicity with tacrolimus / R. Ayres [et al.] // Lancet - 1994. - Vol. 343. - P. 862-3","Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation / B. Forgacs [et al.] // Transplant. Proc. - 2005. - Vol. 37. - P. 1912-14","Пизова, Н. Синдром обратимой задней лейкоэнцефалопатии при системной красной волчанке / Н. Пизова // Неврологический журнал. - 2014. - №19 (6). - С. 44-49","Dillon, W.P. The reversible posterior cerebral edema syndrome [comment] / W.P. Dillon, H. Rowley // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 591","Expressive dysphasia possibly related to FK506 in two liver transplant recipients / J. Reyes [et al.] // Transplantation - 1990. - Vol. 50. - P. 1043-1045","Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation / L. Shutter [et al.] // Neurology - 1993. - Vol. 43. - P. 2417-2418","MR imaging of reversible cyclosporin A-induced neurotoxicity / C. Truwit [et al.] // AJNR Am. J. Neuroradiol. - 1991. - Vol. 12. - P. 651-659","A reversible leukoencephalopathy syndrome / J. Hinchey [et al.] // N. Engl. J. Med. - 1996. - Vol. 334. - P. 494-500","Albayram, S. MR imaging findings of cortical blindness following cerebral angiography: is this entity related to posterior reversible leukoencephalopathy? / S. Albayram, H. Ozer // Am. J. Neuroradiol. - 2005. - Vol. 26. - P. 193","Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler [et al.] // Am. J. Neuroradiol. - 2002. - Vol. 23. - P. 833-7","Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay / T. Kinoshita [et al.] // Clin. Imag. - 2003. - Vol. 27. - P. 307-15","Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping / K. Ahn [et al.] // Neuroradiology. - 2004. - Vol. 46. - P. 978-83","Immunosuppression-induced leukoencephalopathy from tacrolimus / S. Small [et al.] // Ann. Neurol. - 1996. - Vol. 40. - P. 575-580","Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome / Y. Ito [et al.] // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 415-417","Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI / H. Ay [et al.] // Neurology. - 1998. - Vol. 15. - P. 1369-1376","Transient neurotoxicity associated with FK506: MR findings / N. Tomura [et al.] // J. Comput. Assist. Tomogr. - 1998. - Vol. 22. - P. 505-507","Neurologic complications in adult living donor liver transplant recipients / B. Kim [et al.] // Clin. Transplant. - 2007. - Vol. 21, № 4. - P. 544-547","Adams, R. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients / R. Adams, M. Victor, E. Mancall // AMA Arch. Neurol. Psychiatry. - 1959. - Vol. 81. - P. 154-172","Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus / T. Starzl [et al.] // Ann. Surg. - 1978. - Vol. 187, № 3. - P. 236-240","Brown, W.D. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis / W. D. Brown // Curr. Opin.Neurol. - 2000. - Vol. 13. - P. 691-697","Newell, K.L. Central pontine myelinolysis at autopsy; a twelve year retrospective analysis / K.L. Newell, B.K. Kleinschmidt-DeMasters // J. Neurol. Sci. - 1996. - Vol. 142. - P. 1394-1399","Central pontine and extrapontine myelinolysis: a rare and fatal complication after liver transplantation / P. Cascales Campos [et al.] // Transplant. Proc. - 2011. - Vol. 43, № 6. - P. 2237-2238","Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation / K. Fukazawa [et al.] // Ann. Transplant. - 2011. - Vol. 16, № 3. - P. 139-142","Neurological complications of liver cirrhosis and liver transplant / G. Ardizzone [et al.] // Transplant. Proc. - 2006. - Vol. 38, № 3. - P. 789-792","Price, B.H. Behavioral manifestations of central pontine myelinolysis / B.H. Price, M.M. Mesulam // Arch. Neurol. - 1987. - Vol. 44. - P. 671-673","Soupart, A. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia / A. Soupart, M. Ngassa, G. Decaux // Clin. Nephrol. - 1999. - Vol. 51. - P. 383-386","Harris, C.P. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? / C.P. Harris, J.J. Townsend, J.R. Baringer // J. Neurol. Neurosurg. Psychiatry. - 1993. - Vol. 56. - P. 626-632","Mittal, R. Management of hyponatraemia / R. Mittal, H. Sheftel, Y Demssie // Br. J. Hosp. Med. (Lond). - 2011. - Vol. 72, № 2. - P. 22-25","Possible causes of central pontine myelinolysis after liver transplantation / J. Yu [et al.] //World J. Gastroenterol. - 2004. - Vol. 10, № 17. - P. 2540-2543","Clinical and radiologic correlations of central pontine myelinolysis syndrome / J. Graff-Radford [et al.] // Mayo Clin. Proc. - 2011. - Vol. 86, № 11. - P. 1063-1067","Мельничук, П.В. Инфекционные и паразитарные заболевания нервной системы. Абсцесс мозга // Болезни нервной системы/ под ред. Н.Н. Яхно / П.В. Мельничук, Д.Р. Штульман. - М.: МЕДИЦИНА, 2007. - Т. 1. - 340 с","Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression / R. Selby [et al.] // Arch. Surg. - 1997. - Vol. 132. - P. 304-310","Baddley, J.W. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features / J. Baddley, D. Salzman, P. Pappas // Clin. Transplant. - 2002. - Vol. 16. - P. 419-424","Pseudallscheria boydii (Anamorph Scedosporium apiospermum) infection in organ transplant recipients in a tertiary medical center and review of the literature / B. Castiglioni [et al.] // Medicine - 2002. - Vol. 81. - P. 333-348","Disseminated scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report / P. Rogasi [et al.] // Transplant. Proc. -2007. - Vol. 39. - P. 2033-2035","Disseminated pseudallescheria boydii (scedosporium apiospermum) infection in a renal transplant patient / E. Campagnaro [et al.] // Transpl. Infect. Dis. - 2002. - Vol. 4. - P. 207-211","Walker, D.H. Disseminated petriellidosis (allescheriasis) / D. Walker, T. Adamec, M. Krigman // Arch. Pathol. Lab. Med. - 1978. - Vol. 102. - P. 158-160","Bilateral pseudallescheria boydii endophthalmitis in an immunocompromised patient / J. Caya [et al.] // Wis. Med. J. - 1988. - Vol. 87. - P. 11-14","Nesky, M.A. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis / M. Nesky, E. McDougal, J. Peacock // Clin. Infect. Dis. - 2000. - Vol. 31. - P. 673-677","Lavarde, V. Brain abscess due to pseudallescheria boydii in a renal transplant patient / V. Lavarde, F. Traore, D. Farge // Bull. Soc. Fr. Mycol. Medical. - 1989. - Vol. 18. - P. 149-152","Infection due to scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by pseudallescheria boydii / M. Montejo [et al.] // Sc. Mycoses. - 2002. - Vol. 45. - P. 418-427","Pseudallescheria boydii brain abscess in a renal transplant recipient: first case report in southeast Asia / B. Satirapoj [et al.] // Transplant. Proc. - 2008. - Vol. 40. - P. 2425-2427","Treatment of a brain abscess caused by scedosporium apiospermum and phaeoacremonium parasiticum in a renal transplant recipient / N. Larbcharoensub [et al.] // Southeast Asian J. Trop. Med. Public Health - 2013. - Vol. 44. - P. 484-489","Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation / J. Suzuki [et al.] // Transpl. Infect. Dis. - 2012. - Vol. 14, № 4. - P. 7-12. doi: 10.1111/j.1399-3062.2012.00720.x","Herpesvirus hominis type 2 meningoencephalitis following renal transplantation / CC. Jr. Linnemann [et al.] // Am. J. Med. - 1976. - Vol. 61, № 5. - P. 703-708","Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem celltransplant recipients / K. Fujimaki [et al.] // Int. J. Hematol. - 2006. - Vol. 84, № 5. - P. 432-437"],"dc.citation.en":["Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity / B. Appignani [et al.] // AJR Am. J. Roentgenol. - 1996. - Vol. 166. - P. 683-688","Государственный реестр лекарственных средств. Официальное издание: в 2 т.- М.: Медицинский совет, 2009. - Т.2, ч.1. - 568 с.; ч.2. - 560 с","Neurotoxicity in the setting of pediatric atopic dermatitis treated with modified cyclosporine and itraconazole / S. Bayers [et al.] // J. Am. Acad. Dermatol. - 2013. - Vol. 69. - P. e177-8","Interaction between tacrolimus and nefazodone in a stable renal transplant recipient / A. Olyaei [et al.] // Pharmacotherapy. - 1998. - Vol. 18. - P. 1356-1359","Wijdicks, E.F. Neurotoxicity of immunosuppressive drug / E.F. Wijdicks // Liver Transpl. - 2001. - Vol. 7. - P. 937-942","Ташенова, А. Транспортная система гликопротеина-Рифармакокинетика лекарственных средств / А. Ташенова // Биомедицина. - 2010. - № 4. - С. 24-32","Neurologic complications of FK 506 / B. Eidelman [et al.] // Transplant. Proc. - 1991. - Vol. 23. - P. 3175-3178","FK506-induced neurotoxicity in liver transplantation / E. Wijdicks [et al.] // Ann. Neurol. - 1994. - Vol. 35. - P. 498-501","Sensorimotor neuropathy resembling CIDP in patients receiving FK506 / J. Wilson [et al.] // Muscle Nerve. - 1994. - Vol. 17. - P. 528-532","Peripheral neurotoxicity with tacrolimus / R. Ayres [et al.] // Lancet - 1994. - Vol. 343. - P. 862-3","Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation / B. Forgacs [et al.] // Transplant. Proc. - 2005. - Vol. 37. - P. 1912-14","Пизова, Н. Синдром обратимой задней лейкоэнцефалопатии при системной красной волчанке / Н. Пизова // Неврологический журнал. - 2014. - №19 (6). - С. 44-49","Dillon, W.P. The reversible posterior cerebral edema syndrome [comment] / W.P. Dillon, H. Rowley // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 591","Expressive dysphasia possibly related to FK506 in two liver transplant recipients / J. Reyes [et al.] // Transplantation - 1990. - Vol. 50. - P. 1043-1045","Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation / L. Shutter [et al.] // Neurology - 1993. - Vol. 43. - P. 2417-2418","MR imaging of reversible cyclosporin A-induced neurotoxicity / C. Truwit [et al.] // AJNR Am. J. Neuroradiol. - 1991. - Vol. 12. - P. 651-659","A reversible leukoencephalopathy syndrome / J. Hinchey [et al.] // N. Engl. J. Med. - 1996. - Vol. 334. - P. 494-500","Albayram, S. MR imaging findings of cortical blindness following cerebral angiography: is this entity related to posterior reversible leukoencephalopathy? / S. Albayram, H. Ozer // Am. J. Neuroradiol. - 2005. - Vol. 26. - P. 193","Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler [et al.] // Am. J. Neuroradiol. - 2002. - Vol. 23. - P. 833-7","Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay / T. Kinoshita [et al.] // Clin. Imag. - 2003. - Vol. 27. - P. 307-15","Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping / K. Ahn [et al.] // Neuroradiology. - 2004. - Vol. 46. - P. 978-83","Immunosuppression-induced leukoencephalopathy from tacrolimus / S. Small [et al.] // Ann. Neurol. - 1996. - Vol. 40. - P. 575-580","Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome / Y. Ito [et al.] // AJNR Am. J. Neuroradiol. - 1998. - Vol. 19. - P. 415-417","Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI / H. Ay [et al.] // Neurology. - 1998. - Vol. 15. - P. 1369-1376","Transient neurotoxicity associated with FK506: MR findings / N. Tomura [et al.] // J. Comput. Assist. Tomogr. - 1998. - Vol. 22. - P. 505-507","Neurologic complications in adult living donor liver transplant recipients / B. Kim [et al.] // Clin. Transplant. - 2007. - Vol. 21, № 4. - P. 544-547","Adams, R. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients / R. Adams, M. Victor, E. Mancall // AMA Arch. Neurol. Psychiatry. - 1959. - Vol. 81. - P. 154-172","Acute neurological complications after liver transplantation with particular reference to intraoperative cerebral air embolus / T. Starzl [et al.] // Ann. Surg. - 1978. - Vol. 187, № 3. - P. 236-240","Brown, W.D. Osmotic demyelination disorders: central pontine and extrapontine myelinolysis / W. D. Brown // Curr. Opin.Neurol. - 2000. - Vol. 13. - P. 691-697","Newell, K.L. Central pontine myelinolysis at autopsy; a twelve year retrospective analysis / K.L. Newell, B.K. Kleinschmidt-DeMasters // J. Neurol. Sci. - 1996. - Vol. 142. - P. 1394-1399","Central pontine and extrapontine myelinolysis: a rare and fatal complication after liver transplantation / P. Cascales Campos [et al.] // Transplant. Proc. - 2011. - Vol. 43, № 6. - P. 2237-2238","Central pontine myelinolysis (CPM) associated with tacrolimus (FK506) after liver transplantation / K. Fukazawa [et al.] // Ann. Transplant. - 2011. - Vol. 16, № 3. - P. 139-142","Neurological complications of liver cirrhosis and liver transplant / G. Ardizzone [et al.] // Transplant. Proc. - 2006. - Vol. 38, № 3. - P. 789-792","Price, B.H. Behavioral manifestations of central pontine myelinolysis / B.H. Price, M.M. Mesulam // Arch. Neurol. - 1987. - Vol. 44. - P. 671-673","Soupart, A. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia / A. Soupart, M. Ngassa, G. Decaux // Clin. Nephrol. - 1999. - Vol. 51. - P. 383-386","Harris, C.P. Symptomatic hyponatraemia: can myelinolysis be prevented by treatment? / C.P. Harris, J.J. Townsend, J.R. Baringer // J. Neurol. Neurosurg. Psychiatry. - 1993. - Vol. 56. - P. 626-632","Mittal, R. Management of hyponatraemia / R. Mittal, H. Sheftel, Y Demssie // Br. J. Hosp. Med. (Lond). - 2011. - Vol. 72, № 2. - P. 22-25","Possible causes of central pontine myelinolysis after liver transplantation / J. Yu [et al.] //World J. Gastroenterol. - 2004. - Vol. 10, № 17. - P. 2540-2543","Clinical and radiologic correlations of central pontine myelinolysis syndrome / J. Graff-Radford [et al.] // Mayo Clin. Proc. - 2011. - Vol. 86, № 11. - P. 1063-1067","Мельничук, П.В. Инфекционные и паразитарные заболевания нервной системы. Абсцесс мозга // Болезни нервной системы/ под ред. Н.Н. Яхно / П.В. Мельничук, Д.Р. Штульман. - М.: МЕДИЦИНА, 2007. - Т. 1. - 340 с","Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression / R. Selby [et al.] // Arch. Surg. - 1997. - Vol. 132. - P. 304-310","Baddley, J.W. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features / J. Baddley, D. Salzman, P. Pappas // Clin. Transplant. - 2002. - Vol. 16. - P. 419-424","Pseudallscheria boydii (Anamorph Scedosporium apiospermum) infection in organ transplant recipients in a tertiary medical center and review of the literature / B. Castiglioni [et al.] // Medicine - 2002. - Vol. 81. - P. 333-348","Disseminated scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report / P. Rogasi [et al.] // Transplant. Proc. -2007. - Vol. 39. - P. 2033-2035","Disseminated pseudallescheria boydii (scedosporium apiospermum) infection in a renal transplant patient / E. Campagnaro [et al.] // Transpl. Infect. Dis. - 2002. - Vol. 4. - P. 207-211","Walker, D.H. Disseminated petriellidosis (allescheriasis) / D. Walker, T. Adamec, M. Krigman // Arch. Pathol. Lab. Med. - 1978. - Vol. 102. - P. 158-160","Bilateral pseudallescheria boydii endophthalmitis in an immunocompromised patient / J. Caya [et al.] // Wis. Med. J. - 1988. - Vol. 87. - P. 11-14","Nesky, M.A. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis / M. Nesky, E. McDougal, J. Peacock // Clin. Infect. Dis. - 2000. - Vol. 31. - P. 673-677","Lavarde, V. Brain abscess due to pseudallescheria boydii in a renal transplant patient / V. Lavarde, F. Traore, D. Farge // Bull. Soc. Fr. Mycol. Medical. - 1989. - Vol. 18. - P. 149-152","Infection due to scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by pseudallescheria boydii / M. Montejo [et al.] // Sc. Mycoses. - 2002. - Vol. 45. - P. 418-427","Pseudallescheria boydii brain abscess in a renal transplant recipient: first case report in southeast Asia / B. Satirapoj [et al.] // Transplant. Proc. - 2008. - Vol. 40. - P. 2425-2427","Treatment of a brain abscess caused by scedosporium apiospermum and phaeoacremonium parasiticum in a renal transplant recipient / N. Larbcharoensub [et al.] // Southeast Asian J. Trop. Med. Public Health - 2013. - Vol. 44. - P. 484-489","Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation / J. Suzuki [et al.] // Transpl. Infect. Dis. - 2012. - Vol. 14, № 4. - P. 7-12. doi: 10.1111/j.1399-3062.2012.00720.x","Herpesvirus hominis type 2 meningoencephalitis following renal transplantation / CC. Jr. Linnemann [et al.] // Am. J. Med. - 1976. - Vol. 61, № 5. - P. 703-708","Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem celltransplant recipients / K. Fujimaki [et al.] // Int. J. Hematol. - 2006. - Vol. 84, № 5. - P. 432-437"],"dc.date.accessioned_dt":"2021-01-14T11:50:32Z","dc.date.accessioned":["2021-01-14T11:50:32Z"],"dc.date.available":["2021-01-14T11:50:32Z"],"dateIssued":["2017-01-01"],"dateIssued_keyword":["2017-01-01","2017"],"dateIssued_ac":["2017-01-01\n|||\n2017-01-01","2017"],"dateIssued.year":[2017],"dateIssued.year_sort":"2017","dc.date.issued_dt":"2017-01-01T00:00:00Z","dc.date.issued":["2017-01-01"],"dc.date.issued_stored":["2017-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.identifier.uri":["http://hdl.handle.net/123456789/5098"],"dc.issue.number":["5"],"dc.issue.volume":["12"],"dc.origin":["https://medvestb.elpub.ru/jour/article/view/177"],"dc.pages":["152-157"],"dc.rights":["CC BY 4.0"],"dc.section":["ОБЗОР ЛИТЕРАТУРЫ"],"dc.section.ru":["ОБЗОР ЛИТЕРАТУРЫ"],"dc.source":["Bashkortostan Medical Journal","Медицинский вестник Башкортостана"],"dc.source.en":["Bashkortostan Medical Journal"],"dc.source.ru":["Медицинский вестник Башкортостана"],"subject":["нейропатия","синдром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз","абсцесс головного мозга","вирусный менингоэнцефалит","трансплантация","такролимус","neuropathy","reversible posterior leukoencephalopathy syndrome","central pontine myelinolysis","brain abscess","viral meningoencephalitis","transplantation","tacrolimus"],"subject_keyword":["нейропатия","нейропатия","синдром обратимой задней лейкоэнцефалопатии","синдром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз","центральный понтинный миелинолиз","абсцесс головного мозга","абсцесс головного мозга","вирусный менингоэнцефалит","вирусный менингоэнцефалит","трансплантация","трансплантация","такролимус","такролимус","neuropathy","neuropathy","reversible posterior leukoencephalopathy syndrome","reversible posterior leukoencephalopathy syndrome","central pontine myelinolysis","central pontine myelinolysis","brain abscess","brain abscess","viral meningoencephalitis","viral meningoencephalitis","transplantation","transplantation","tacrolimus","tacrolimus"],"subject_ac":["нейропатия\n|||\nнейропатия","синдром обратимой задней лейкоэнцефалопатии\n|||\nсиндром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз\n|||\nцентральный понтинный миелинолиз","абсцесс головного мозга\n|||\nабсцесс головного мозга","вирусный менингоэнцефалит\n|||\nвирусный менингоэнцефалит","трансплантация\n|||\nтрансплантация","такролимус\n|||\nтакролимус","neuropathy\n|||\nneuropathy","reversible posterior leukoencephalopathy syndrome\n|||\nreversible posterior leukoencephalopathy syndrome","central pontine myelinolysis\n|||\ncentral pontine myelinolysis","brain abscess\n|||\nbrain abscess","viral meningoencephalitis\n|||\nviral meningoencephalitis","transplantation\n|||\ntransplantation","tacrolimus\n|||\ntacrolimus"],"subject_tax_0_filter":["нейропатия\n|||\nнейропатия","синдром обратимой задней лейкоэнцефалопатии\n|||\nсиндром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз\n|||\nцентральный понтинный миелинолиз","абсцесс головного мозга\n|||\nабсцесс головного мозга","вирусный менингоэнцефалит\n|||\nвирусный менингоэнцефалит","трансплантация\n|||\nтрансплантация","такролимус\n|||\nтакролимус","neuropathy\n|||\nneuropathy","reversible posterior leukoencephalopathy syndrome\n|||\nreversible posterior leukoencephalopathy syndrome","central pontine myelinolysis\n|||\ncentral pontine myelinolysis","brain abscess\n|||\nbrain abscess","viral meningoencephalitis\n|||\nviral meningoencephalitis","transplantation\n|||\ntransplantation","tacrolimus\n|||\ntacrolimus"],"subject_filter":["нейропатия\n|||\nнейропатия","синдром обратимой задней лейкоэнцефалопатии\n|||\nсиндром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз\n|||\nцентральный понтинный миелинолиз","абсцесс головного мозга\n|||\nабсцесс головного мозга","вирусный менингоэнцефалит\n|||\nвирусный менингоэнцефалит","трансплантация\n|||\nтрансплантация","такролимус\n|||\nтакролимус","neuropathy\n|||\nneuropathy","reversible posterior leukoencephalopathy syndrome\n|||\nreversible posterior leukoencephalopathy syndrome","central pontine myelinolysis\n|||\ncentral pontine myelinolysis","brain abscess\n|||\nbrain abscess","viral meningoencephalitis\n|||\nviral meningoencephalitis","transplantation\n|||\ntransplantation","tacrolimus\n|||\ntacrolimus"],"dc.subject_mlt":["нейропатия","синдром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз","абсцесс головного мозга","вирусный менингоэнцефалит","трансплантация","такролимус","neuropathy","reversible posterior leukoencephalopathy syndrome","central pontine myelinolysis","brain abscess","viral meningoencephalitis","transplantation","tacrolimus"],"dc.subject":["нейропатия","синдром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз","абсцесс головного мозга","вирусный менингоэнцефалит","трансплантация","такролимус","neuropathy","reversible posterior leukoencephalopathy syndrome","central pontine myelinolysis","brain abscess","viral meningoencephalitis","transplantation","tacrolimus"],"dc.subject.ru":["нейропатия","синдром обратимой задней лейкоэнцефалопатии","центральный понтинный миелинолиз","абсцесс головного мозга","вирусный менингоэнцефалит","трансплантация","такролимус","neuropathy","reversible posterior leukoencephalopathy syndrome","central pontine myelinolysis","brain abscess","viral meningoencephalitis","transplantation","tacrolimus"],"title":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"title_keyword":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"title_ac":["posttransplantation disoders of the nervous system\n|||\nPOSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","посттрансплатанционные расстройства нервной системы\n|||\nПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"dc.title_sort":"POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","dc.title_hl":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"dc.title_mlt":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"dc.title":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"dc.title_stored":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nru"],"dc.title.en":["POSTTRANSPLANTATION DISODERS OF THE NERVOUS SYSTEM"],"dc.title.ru":["ПОСТТРАНСПЛАТАНЦИОННЫЕ РАССТРОЙСТВА НЕРВНОЙ СИСТЕМЫ"],"publication_grp":["123456789/5098"],"bi_4_dis_filter":["нейропатия\n|||\nнейропатия","центральный понтинный миелинолиз\n|||\nцентральный понтинный миелинолиз","синдром обратимой задней лейкоэнцефалопатии\n|||\nсиндром обратимой задней лейкоэнцефалопатии","абсцесс головного мозга\n|||\nабсцесс головного мозга","такролимус\n|||\nтакролимус","viral meningoencephalitis\n|||\nviral meningoencephalitis","transplantation\n|||\ntransplantation","вирусный менингоэнцефалит\n|||\nвирусный менингоэнцефалит","трансплантация\n|||\nтрансплантация","reversible posterior leukoencephalopathy syndrome\n|||\nreversible posterior leukoencephalopathy syndrome","central pontine myelinolysis\n|||\ncentral pontine myelinolysis","neuropathy\n|||\nneuropathy","tacrolimus\n|||\ntacrolimus","brain abscess\n|||\nbrain abscess"],"bi_4_dis_partial":["синдром обратимой задней лейкоэнцефалопатии","tacrolimus","вирусный менингоэнцефалит","central pontine myelinolysis","такролимус","трансплантация","reversible posterior leukoencephalopathy syndrome","абсцесс головного мозга","viral meningoencephalitis","нейропатия","transplantation","neuropathy","brain abscess","центральный понтинный миелинолиз"],"bi_4_dis_value_filter":["синдром обратимой задней лейкоэнцефалопатии","tacrolimus","вирусный менингоэнцефалит","central pontine myelinolysis","такролимус","трансплантация","reversible posterior leukoencephalopathy syndrome","абсцесс головного мозга","viral meningoencephalitis","нейропатия","transplantation","neuropathy","brain abscess","центральный понтинный миелинолиз"],"bi_sort_1_sort":"posttransplantation disoders of the nervous system","bi_sort_2_sort":"2017","bi_sort_3_sort":"2021-01-14T11:50:32Z","read":["g0"],"_version_":1702068439783309312},{"SolrIndexer.lastIndexed":"2021-04-20T11:26:42.462Z","search.uniqueid":"2-5046","search.resourcetype":2,"search.resourceid":5046,"handle":"123456789/5959","location":["m229","l684"],"location.comm":["229"],"location.coll":["684"],"withdrawn":"false","discoverable":"true","author":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"author_keyword":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"author_ac":["meshcheryakova, s\n|||\nMeshcheryakova, S","shumadalova, a\n|||\nShumadalova, A","beylerli, o\n|||\nBeylerli, O","gareev, i\n|||\nGareev, I"],"author_filter":["meshcheryakova, s\n|||\nMeshcheryakova, S","shumadalova, a\n|||\nShumadalova, A","beylerli, o\n|||\nBeylerli, O","gareev, i\n|||\nGareev, I"],"dc.contributor.author_hl":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"dc.contributor.author_mlt":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"dc.contributor.author":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"dc.contributor.author_stored":["Meshcheryakova, S\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Shumadalova, A\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Beylerli, O\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Gareev, I\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.contributor.author.en":["Meshcheryakova, S","Shumadalova, A","Beylerli, O","Gareev, I"],"dc.date.accessioned_dt":"2021-04-16T10:02:40Z","dc.date.accessioned":["2021-04-16T10:02:40Z"],"dc.date.available":["2021-04-16T10:02:40Z"],"dateIssued":["2021-01-01"],"dateIssued_keyword":["2021-01-01","2021"],"dateIssued_ac":["2021-01-01\n|||\n2021-01-01","2021"],"dateIssued.year":[2021],"dateIssued.year_sort":"2021","dc.date.issued_dt":"2021-01-01T00:00:00Z","dc.date.issued":["2021-01-01"],"dc.date.issued_stored":["2021-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.identifier.issn":["1848-7718"],"dc.identifier.uri":["http://hdl.handle.net/123456789/5959"],"dc.description.abstract_hl":["The synthesis and antimicrobial evaluation of new 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives was investigated. According to the literature, there are a lot of antimicrobial agents among the pyrimidines and hydrazides, and therefore it seems promising to use 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide as a base object for synthesizing new biologically active substances. 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide was obtained by the hydrazinolysis of ethyl thioacetate, using a 3-fold molar excess of 85 % hydrazine hydrate in ethanol, at room temperature. Interaction of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-acetohydrazide with ketones during boiling in ethanol yielded N-ylidenehydrazides. The solid obtained by concentration was collected, and then purified by recrystallization. The new compounds were characterized by H-1, C-13 NMR, IR spectroscopy and elemental analysis. The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold broth (pH 7.2 - 7.4) dilution methods, in comparison with the clinical used drugs, ceftriaxone and Pimafucin. The structure-activity studies showed that, depending on the nature of the hydrazide fragment, the newly synthesized compounds exhibited varying degrees of microbial inhibition. Within the same series the antimicrobial activity depends on the nature of the substituent attached to the benzene ring. The investigation of antibacterial screening data revealed that the compounds N '-[1-(4-aminophenyl)ethylidene]-2-[6-methyl4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N' -[1-(4-hydroxyphenyl)ethylidene]-2-[6-methyl-4(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N'-[1- (2,5-dihydroxyphenyl) ethylidene]-2-[6-methyl4-(thietan-3-yloxy)-pyrimidin-2-ylthio]acetohydrazide were found to be more potent than the other synthesized analogues. (C) 2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/)."],"dc.description.abstract":["The synthesis and antimicrobial evaluation of new 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives was investigated. According to the literature, there are a lot of antimicrobial agents among the pyrimidines and hydrazides, and therefore it seems promising to use 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide as a base object for synthesizing new biologically active substances. 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide was obtained by the hydrazinolysis of ethyl thioacetate, using a 3-fold molar excess of 85 % hydrazine hydrate in ethanol, at room temperature. Interaction of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-acetohydrazide with ketones during boiling in ethanol yielded N-ylidenehydrazides. The solid obtained by concentration was collected, and then purified by recrystallization. The new compounds were characterized by H-1, C-13 NMR, IR spectroscopy and elemental analysis. The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold broth (pH 7.2 - 7.4) dilution methods, in comparison with the clinical used drugs, ceftriaxone and Pimafucin. The structure-activity studies showed that, depending on the nature of the hydrazide fragment, the newly synthesized compounds exhibited varying degrees of microbial inhibition. Within the same series the antimicrobial activity depends on the nature of the substituent attached to the benzene ring. The investigation of antibacterial screening data revealed that the compounds N '-[1-(4-aminophenyl)ethylidene]-2-[6-methyl4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N' -[1-(4-hydroxyphenyl)ethylidene]-2-[6-methyl-4(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N'-[1- (2,5-dihydroxyphenyl) ethylidene]-2-[6-methyl4-(thietan-3-yloxy)-pyrimidin-2-ylthio]acetohydrazide were found to be more potent than the other synthesized analogues. (C) 2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/)."],"dc.description.abstract.en":["The synthesis and antimicrobial evaluation of new 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives was investigated. According to the literature, there are a lot of antimicrobial agents among the pyrimidines and hydrazides, and therefore it seems promising to use 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide as a base object for synthesizing new biologically active substances. 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide was obtained by the hydrazinolysis of ethyl thioacetate, using a 3-fold molar excess of 85 % hydrazine hydrate in ethanol, at room temperature. Interaction of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]-acetohydrazide with ketones during boiling in ethanol yielded N-ylidenehydrazides. The solid obtained by concentration was collected, and then purified by recrystallization. The new compounds were characterized by H-1, C-13 NMR, IR spectroscopy and elemental analysis. The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold broth (pH 7.2 - 7.4) dilution methods, in comparison with the clinical used drugs, ceftriaxone and Pimafucin. The structure-activity studies showed that, depending on the nature of the hydrazide fragment, the newly synthesized compounds exhibited varying degrees of microbial inhibition. Within the same series the antimicrobial activity depends on the nature of the substituent attached to the benzene ring. The investigation of antibacterial screening data revealed that the compounds N '-[1-(4-aminophenyl)ethylidene]-2-[6-methyl4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N' -[1-(4-hydroxyphenyl)ethylidene]-2-[6-methyl-4(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide, N'-[1- (2,5-dihydroxyphenyl) ethylidene]-2-[6-methyl4-(thietan-3-yloxy)-pyrimidin-2-ylthio]acetohydrazide were found to be more potent than the other synthesized analogues. (C) 2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/)."],"dc.publisher":["IAPC PUBLISHING, S ALICA 4, ZAGREB, HR-10000, CROATIA"],"dc.publisher.en":["IAPC PUBLISHING, S ALICA 4, ZAGREB, HR-10000, CROATIA"],"dc.relation.ispartofseries":["ADMET AND DMPK;т. 9 № 2"],"dc.relation.ispartofseries.en":["ADMET AND DMPK;т. 9 № 2"],"subject":["thietan","thiopyrimidine","antibacterial and antifungal activities","Web of Science"],"subject_keyword":["thietan","thietan","thiopyrimidine","thiopyrimidine","antibacterial and antifungal activities","antibacterial and antifungal activities","Web of Science","Web of Science"],"subject_ac":["thietan\n|||\nthietan","thiopyrimidine\n|||\nthiopyrimidine","antibacterial and antifungal activities\n|||\nantibacterial and antifungal activities","web of science\n|||\nWeb of Science"],"subject_tax_0_filter":["thietan\n|||\nthietan","thiopyrimidine\n|||\nthiopyrimidine","antibacterial and antifungal activities\n|||\nantibacterial and antifungal activities","web of science\n|||\nWeb of Science"],"subject_filter":["thietan\n|||\nthietan","thiopyrimidine\n|||\nthiopyrimidine","antibacterial and antifungal activities\n|||\nantibacterial and antifungal activities","web of science\n|||\nWeb of Science"],"dc.subject_mlt":["thietan","thiopyrimidine","antibacterial and antifungal activities","Web of Science"],"dc.subject":["thietan","thiopyrimidine","antibacterial and antifungal activities","Web of Science"],"dc.subject.en":["thietan","thiopyrimidine","antibacterial and antifungal activities","Web of Science"],"title":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"title_keyword":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"title_ac":["synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives\n|||\nSynthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title_sort":"Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives","dc.title_hl":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title_mlt":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title_stored":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.title.en":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title.alternative":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.title.alternative.en":["Synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives"],"dc.type":["Article"],"dc.type.ru_RU":["Article"],"dc.doi":["10.5599/admet.941"],"publication_grp":["123456789/5959"],"bi_2_dis_filter":["beylerli, o\n|||\nBeylerli, O","meshcheryakova, s\n|||\nMeshcheryakova, S","shumadalova, a\n|||\nShumadalova, A","gareev, i\n|||\nGareev, I"],"bi_2_dis_partial":["Shumadalova, A","Gareev, I","Meshcheryakova, S","Beylerli, O"],"bi_2_dis_value_filter":["Shumadalova, A","Gareev, I","Meshcheryakova, S","Beylerli, O"],"bi_4_dis_filter":["thiopyrimidine\n|||\nthiopyrimidine","thietan\n|||\nthietan","web of science\n|||\nWeb of Science","antibacterial and antifungal activities\n|||\nantibacterial and antifungal activities"],"bi_4_dis_partial":["antibacterial and antifungal activities","Web of Science","thietan","thiopyrimidine"],"bi_4_dis_value_filter":["antibacterial and antifungal activities","Web of Science","thietan","thiopyrimidine"],"bi_sort_1_sort":"synthesis and biological activity of 2-[6-methyl-4-(thietan-3-yloxy)pyrimidin-2-ylthio]acetohydrazide derivatives","bi_sort_2_sort":"2021","bi_sort_3_sort":"2021-04-16T10:02:40Z","read":["g0"],"_version_":1697558563362177024},{"SolrIndexer.lastIndexed":"2022-05-13T06:32:39.89Z","search.uniqueid":"2-5768","search.resourcetype":2,"search.resourceid":5768,"handle":"123456789/6673","location":["m229","l684"],"location.comm":["229"],"location.coll":["684"],"withdrawn":"false","discoverable":"true","author":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"author_keyword":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"author_ac":["talybov, rustam\n|||\nTalybov, Rustam","beylerli, ozal\n|||\nBeylerli, Ozal","mochalov, vadim\n|||\nMochalov, Vadim","prokopenko, alexey\n|||\nProkopenko, Alexey","ilyasova, tatiana\n|||\nIlyasova, Tatiana","trofimova, tatiana\n|||\nTrofimova, Tatiana","sufianov, albert\n|||\nSufianov, Albert","guang, yang\n|||\nGuang, Yang"],"author_filter":["talybov, rustam\n|||\nTalybov, Rustam","beylerli, ozal\n|||\nBeylerli, Ozal","mochalov, vadim\n|||\nMochalov, Vadim","prokopenko, alexey\n|||\nProkopenko, Alexey","ilyasova, tatiana\n|||\nIlyasova, Tatiana","trofimova, tatiana\n|||\nTrofimova, Tatiana","sufianov, albert\n|||\nSufianov, Albert","guang, yang\n|||\nGuang, Yang"],"dc.contributor.author_hl":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"dc.contributor.author_mlt":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"dc.contributor.author":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"dc.contributor.author_stored":["Talybov, Rustam\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Beylerli, Ozal\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Mochalov, Vadim\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Prokopenko, Alexey\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Ilyasova, Tatiana\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Trofimova, Tatiana\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Sufianov, Albert\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen","Guang, Yang\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.contributor.author.en":["Talybov, Rustam","Beylerli, Ozal","Mochalov, Vadim","Prokopenko, Alexey","Ilyasova, Tatiana","Trofimova, Tatiana","Sufianov, Albert","Guang, Yang"],"dc.date.accessioned_dt":"2022-05-13T06:29:42Z","dc.date.accessioned":["2022-05-13T06:29:42Z"],"dc.date.available":["2022-05-13T06:29:42Z"],"dateIssued":["2022-01-01"],"dateIssued_keyword":["2022-01-01","2022"],"dateIssued_ac":["2022-01-01\n|||\n2022-01-01","2022"],"dateIssued.year":[2022],"dateIssued.year_sort":"2022","dc.date.issued_dt":"2022-01-01T00:00:00Z","dc.date.issued":["2022-01-01"],"dc.date.issued_stored":["2022-01-01\n|||\nnull\n|||\nnull\n|||\nnull\n|||\n"],"dc.description.abstract_hl":["Objective: Primary central nervous system lymphomas (PCNS) are relatively rare tumors, accounting for about 4% of all brain tumors. On neuroimaging, they are characterized by a low MR signal in T1, isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study is to note the lack of effectiveness of the MR/CT perfusion technique in complex multiparametric imaging in the differential diagnosis of primary lymphomas of the central nervous system in comparison with highly malignant gliomas and brain metastases. Materials and Methods: This prospective study included 80 patients with CNS tumors examined/operated at the Federal Center for Neurosurgery (Tyumen, Russia) from 2018 to 2021. The patients were divided into 4 groups: group 1 consisted of 33 cases with primary CNS lymphomas (10 cases with atypical manifestations according to perfusion parameters and 23 cases of classic CNS lymphomas), group 2 with anaplastic astrocytomas—14 cases, group 3—23 cases with glioblastomas and group 4—10 cases with solitary metastatic lesions. The study was carried out on a General Electric Discovery W750 3T magnetic resonance tomograph, a Canon Aquilion One multispiral X-ray computed tomograph (Gadovist 7.5 ml, Yomeron 400 mg−50 ml). Additionally, immunohistochemical analysis was carried out with the following markers: CD3, CD20, CD34, Ki-67, VEGF. Results: It has been established that MR/CT perfusion is not a highly sensitive method for visualizing primary CNS lymphomas, as previously thought, but at the same time, the method has a number of undeniable advantages that make it indispensable in the algorithm of a complex multiparametric diagnostic approach for this type of tumor. Nevertheless, PLCNS is characterized by an atypical manifestation, which is an exception to the rule. Conclusions: The possibilities of neuroimaging of primary lymphomas, even with the use of improved techniques for collecting MR/CT data, are limited and do not always allow reliable differentiation from other neoplasms. Copyright © 2022 Talybov, Beylerli, Mochalov, Prokopenko, Ilyasova, Trofimova, Sufianov and Guang."],"dc.description.abstract":["Objective: Primary central nervous system lymphomas (PCNS) are relatively rare tumors, accounting for about 4% of all brain tumors. On neuroimaging, they are characterized by a low MR signal in T1, isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study is to note the lack of effectiveness of the MR/CT perfusion technique in complex multiparametric imaging in the differential diagnosis of primary lymphomas of the central nervous system in comparison with highly malignant gliomas and brain metastases. Materials and Methods: This prospective study included 80 patients with CNS tumors examined/operated at the Federal Center for Neurosurgery (Tyumen, Russia) from 2018 to 2021. The patients were divided into 4 groups: group 1 consisted of 33 cases with primary CNS lymphomas (10 cases with atypical manifestations according to perfusion parameters and 23 cases of classic CNS lymphomas), group 2 with anaplastic astrocytomas—14 cases, group 3—23 cases with glioblastomas and group 4—10 cases with solitary metastatic lesions. The study was carried out on a General Electric Discovery W750 3T magnetic resonance tomograph, a Canon Aquilion One multispiral X-ray computed tomograph (Gadovist 7.5 ml, Yomeron 400 mg−50 ml). Additionally, immunohistochemical analysis was carried out with the following markers: CD3, CD20, CD34, Ki-67, VEGF. Results: It has been established that MR/CT perfusion is not a highly sensitive method for visualizing primary CNS lymphomas, as previously thought, but at the same time, the method has a number of undeniable advantages that make it indispensable in the algorithm of a complex multiparametric diagnostic approach for this type of tumor. Nevertheless, PLCNS is characterized by an atypical manifestation, which is an exception to the rule. Conclusions: The possibilities of neuroimaging of primary lymphomas, even with the use of improved techniques for collecting MR/CT data, are limited and do not always allow reliable differentiation from other neoplasms. Copyright © 2022 Talybov, Beylerli, Mochalov, Prokopenko, Ilyasova, Trofimova, Sufianov and Guang."],"dc.description.abstract.en":["Objective: Primary central nervous system lymphomas (PCNS) are relatively rare tumors, accounting for about 4% of all brain tumors. On neuroimaging, they are characterized by a low MR signal in T1, isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study is to note the lack of effectiveness of the MR/CT perfusion technique in complex multiparametric imaging in the differential diagnosis of primary lymphomas of the central nervous system in comparison with highly malignant gliomas and brain metastases. Materials and Methods: This prospective study included 80 patients with CNS tumors examined/operated at the Federal Center for Neurosurgery (Tyumen, Russia) from 2018 to 2021. The patients were divided into 4 groups: group 1 consisted of 33 cases with primary CNS lymphomas (10 cases with atypical manifestations according to perfusion parameters and 23 cases of classic CNS lymphomas), group 2 with anaplastic astrocytomas—14 cases, group 3—23 cases with glioblastomas and group 4—10 cases with solitary metastatic lesions. The study was carried out on a General Electric Discovery W750 3T magnetic resonance tomograph, a Canon Aquilion One multispiral X-ray computed tomograph (Gadovist 7.5 ml, Yomeron 400 mg−50 ml). Additionally, immunohistochemical analysis was carried out with the following markers: CD3, CD20, CD34, Ki-67, VEGF. Results: It has been established that MR/CT perfusion is not a highly sensitive method for visualizing primary CNS lymphomas, as previously thought, but at the same time, the method has a number of undeniable advantages that make it indispensable in the algorithm of a complex multiparametric diagnostic approach for this type of tumor. Nevertheless, PLCNS is characterized by an atypical manifestation, which is an exception to the rule. Conclusions: The possibilities of neuroimaging of primary lymphomas, even with the use of improved techniques for collecting MR/CT data, are limited and do not always allow reliable differentiation from other neoplasms. Copyright © 2022 Talybov, Beylerli, Mochalov, Prokopenko, Ilyasova, Trofimova, Sufianov and Guang."],"dc.doi":["10.3389/fsurg.2022.887249"],"dc.identifier.issn":["2296-875X"],"dc.identifier.uri":["http://hdl.handle.net/123456789/6673"],"dc.language.iso":["en"],"dc.language.iso.en":["en"],"dc.publisher":["Frontiers Media S.A."],"dc.publisher.en":["Frontiers Media S.A."],"dc.relation.ispartofseries":["Frontiers in Surgery;т. 9"],"dc.relation.ispartofseries.en":["Frontiers in Surgery;т. 9"],"subject":["CT","MRI","neuroradiology","PCNSL","perfusion","Scopus"],"subject_keyword":["CT","CT","MRI","MRI","neuroradiology","neuroradiology","PCNSL","PCNSL","perfusion","perfusion","Scopus","Scopus"],"subject_ac":["ct\n|||\nCT","mri\n|||\nMRI","neuroradiology\n|||\nneuroradiology","pcnsl\n|||\nPCNSL","perfusion\n|||\nperfusion","scopus\n|||\nScopus"],"subject_tax_0_filter":["ct\n|||\nCT","mri\n|||\nMRI","neuroradiology\n|||\nneuroradiology","pcnsl\n|||\nPCNSL","perfusion\n|||\nperfusion","scopus\n|||\nScopus"],"subject_filter":["ct\n|||\nCT","mri\n|||\nMRI","neuroradiology\n|||\nneuroradiology","pcnsl\n|||\nPCNSL","perfusion\n|||\nperfusion","scopus\n|||\nScopus"],"dc.subject_mlt":["CT","MRI","neuroradiology","PCNSL","perfusion","Scopus"],"dc.subject":["CT","MRI","neuroradiology","PCNSL","perfusion","Scopus"],"dc.subject.en":["CT","MRI","neuroradiology","PCNSL","perfusion","Scopus"],"title":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"title_keyword":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"title_ac":["multiparametric mr imaging features of primary cns lymphomas\n|||\nMultiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title_sort":"Multiparametric MR Imaging Features of Primary CNS Lymphomas","dc.title_hl":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title_mlt":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title_stored":["Multiparametric MR Imaging Features of Primary CNS Lymphomas\n|||\nnull\n|||\nnull\n|||\nnull\n|||\nen"],"dc.title.en":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title.alternative":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.title.alternative.en":["Multiparametric MR Imaging Features of Primary CNS Lymphomas"],"dc.type":["Article"],"publication_grp":["123456789/6673"],"bi_2_dis_filter":["beylerli, ozal\n|||\nBeylerli, Ozal","trofimova, tatiana\n|||\nTrofimova, Tatiana","guang, yang\n|||\nGuang, Yang","mochalov, vadim\n|||\nMochalov, Vadim","prokopenko, alexey\n|||\nProkopenko, Alexey","talybov, rustam\n|||\nTalybov, Rustam","ilyasova, tatiana\n|||\nIlyasova, Tatiana","sufianov, albert\n|||\nSufianov, Albert"],"bi_2_dis_partial":["Guang, Yang","Mochalov, Vadim","Sufianov, Albert","Talybov, Rustam","Beylerli, Ozal","Ilyasova, Tatiana","Prokopenko, Alexey","Trofimova, Tatiana"],"bi_2_dis_value_filter":["Guang, Yang","Mochalov, Vadim","Sufianov, Albert","Talybov, Rustam","Beylerli, Ozal","Ilyasova, Tatiana","Prokopenko, Alexey","Trofimova, Tatiana"],"bi_4_dis_filter":["neuroradiology\n|||\nneuroradiology","perfusion\n|||\nperfusion","mri\n|||\nMRI","ct\n|||\nCT","pcnsl\n|||\nPCNSL","scopus\n|||\nScopus"],"bi_4_dis_partial":["CT","neuroradiology","PCNSL","perfusion","MRI","Scopus"],"bi_4_dis_value_filter":["CT","neuroradiology","PCNSL","perfusion","MRI","Scopus"],"bi_sort_1_sort":"multiparametric mr imaging features of primary cns lymphomas","bi_sort_2_sort":"2022","bi_sort_3_sort":"2022-05-13T06:29:42Z","read":["g0"],"_version_":1732691686748848128}]},"facet_counts":{"facet_queries":{},"facet_fields":{},"facet_dates":{},"facet_ranges":{},"facet_intervals":{}},"highlighting":{"2-4026":{"dc.publisher":["Research Journal of Pharmaceutical, Biological and Chemical Sciences"],"dc.relation.ispartofseries":["RESEARCH JOURNAL OF PHARMACEUTICAL, BIOLOGICAL AND CHEMICAL SCIENCES;Том 7, № 5"],"dc.relation.ispartofseries.en":["RESEARCH JOURNAL OF PHARMACEUTICAL, BIOLOGICAL AND CHEMICAL SCIENCES;Том 7, № 5"],"dc.publisher.en":["Research Journal of Pharmaceutical, Biological and Chemical Sciences"]},"2-5710":{"dc.abstract.en":[" and analytical activities at the NHC were exposed to the combined effects of a complex of harmful chemicals"],"dc.abstract":[" and analytical activities at the NHC were exposed to the combined effects of a complex of harmful chemicals"]},"2-7129":{"bi_4_dis_partial":["chemical composition of hair"],"dc.subject.en":["chemical composition of hair"],"dc.subject":["chemical composition of hair"],"dc.subject_mlt":["chemical composition of hair"],"dc.abstract.en":[", colorectal cancer etc.). This determines the relevance of studying the patterns of this chemical element"],"subject":["chemical composition of hair"],"dc.abstract":[", colorectal cancer etc.). This determines the relevance of studying the patterns of this chemical element"]},"2-5383":{"dc.fullHTML":[" to surgeons to pay attention to the great role of these physico-chemical factors in local interaction"],"dc.fullRISC.en":[" role of these physico-chemical factors in local interaction in treating long-term non-healing wounds"],"dc.title.en":["Physico-Chemical Properties of Antiseptics in Surgery: What is not Taken into Account in Treating"],"dc.title":["Physico-Chemical Properties of Antiseptics in Surgery: What is not Taken into Account in Treating"],"dc.title_hl":["Physico-Chemical Properties of Antiseptics in Surgery: What is not Taken into Account in Treating"],"dc.title_mlt":["Physico-Chemical Properties of Antiseptics in Surgery: What is not Taken into Account in Treating"],"title":["Physico-Chemical Properties of Antiseptics in Surgery: What is not Taken into Account in Treating"],"dc.citation.en":["Urakov A.L. Pus solvents as new drugs with unique physical and chemical property. Reviews"],"dc.fullRISC":[" role of these physico-chemical factors in local interaction in treating long-term non-healing wounds"],"dc.fullHTML.en":[" to surgeons to pay attention to the great role of these physico-chemical factors in local interaction"],"dc.citation.ru":["Urakov A.L. Pus solvents as new drugs with unique physical and chemical property. Reviews"],"dc.abstract.en":[" by such physical and chemical factors of their local interaction as concentration of the main ingredients, osmotic"],"dc.citation":["Urakov A.L. Pus solvents as new drugs with unique physical and chemical property. Reviews"],"dc.abstract":[" by such physical and chemical factors of their local interaction as concentration of the main ingredients, osmotic"]},"2-8043":{"bi_4_dis_partial":["diffuse symmetric lipomatosis"],"dc.subject.en":["diffuse symmetric lipomatosis"],"dc.citation.en":["Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30."],"dc.subject":["diffuse symmetric lipomatosis"],"dc.citation.ru":["Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30."],"dc.subject_mlt":["diffuse symmetric lipomatosis"],"dc.abstract.en":["

Introduction. Diffuse symmetric lipomatosis (Madelung’s disease) is a rare"],"dc.citation":["Madelung O.W. Über den Fetthals (diffuses Lipom des Halses). Arch Klin Chir. 1888;37:106-30."],"subject":["diffuse symmetric lipomatosis"],"dc.abstract":["

Introduction. Diffuse symmetric lipomatosis (Madelung’s disease) is a rare"]},"2-5704":{"bi_4_dis_partial":["chemical modification"],"dc.subject.en":["chemical modification"],"dc.subject":["chemical modification"],"dc.subject_mlt":["chemical modification"],"subject":["chemical modification"]},"2-6393":{"bi_4_dis_partial":["chemical comp"],"dc.subject":["chemical comp"],"dc.subject.ru_RU":["chemical comp"],"dc.subject_mlt":["chemical comp"],"subject":["chemical comp"]},"2-4193":{"dc.citation.en":["Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler"],"dc.citation.ru":["Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler"],"dc.citation":["Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome / F. Eichler"]},"2-5046":{"dc.description.abstract":[". The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold"],"dc.description.abstract.en":[". The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold"],"dc.description.abstract_hl":[". The antibacterial and antifungal activities of the new compounds were analysed using agar diffusion and tenfold"]},"2-5768":{"dc.description.abstract":[", isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study"],"dc.description.abstract.en":[", isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study"],"dc.description.abstract_hl":[", isointense in T2, bright uniform contrast enhancement, and diffusion restriction. The aim of this study"]}}} -->